| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Galectin Therapeutics Inc.$4.06
-0.28 (-6.46%)
D 38Pipeline Score Richly Valued Biotech · Clinical
Market Cap
164.64 M
EPS
-0.41
P/E Ratio
-
Value Trade
531.37 K
SEC Financials
Q1 2026Dilution Risk
40%R&D Expenses
2.23 M
Operating CF
-3.87 M
Total Assets
15.76 M
Total Liabilities
146.00 M
Equity
-131.96 M
D/E Ratio
12,345
5.93 %
Week
9.17 %
1 Month
-14.38 %
3 Month
-55.91 %
6 Month
-42.53 %
5 Year
-79.17 %
All Time
Cash Data
Cash Position
14.11 M
Monthly Burn
1.29 M
Runway
9.3 mo
Burn Trend
SEC Filing
May 15, 2026
Overview
Volume
528.75 K
52 Week Range
1.22 - 7.13
% held by Insiders
28.73 %
% held by Institutions
21.07 %
Enterprise Value
288.45 M
Total Shares
65.85 M
Short %
20.55 %
Float Shares
43.66 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Galectin Therapeutics Inc.
716Total events
3Upcoming
124Tier-1 (high impact)
2012 – 2027Coverage
Upcoming catalysts 3
Event history 713
Q3 2026
◆Trial InitiationbelapectinTrial
Phase 3 protocol submission anticipated in Q3 2026
MASH cirrhosis and portal hypertensionsource ↗
Jun 23, 2026
▲Type C MeetingbelapectinFDA Meeting
Positive Type C meeting with FDA on belapectin Phase 3 program
MASH cirrhosis and portal hypertensionsource ↗
Jun 23, 2026
▲FDA Feedback ReceivedbelapectinFDA Meeting
FDA accepted central endoscopy review methodology for Phase 3
MASH cirrhosis and portal hypertensionsource ↗
Jun 2026
May 30, 2026
◆Oral PresentationbelapectinPresentation
Oral presentation: Belapectin reduces varices development in high-risk MASH cirrhosis by modulating fibrogenesis balance as reflected by Pro-C3/CTX-III ratio
MASH cirrhosissource ↗
May 28, 2026
◆Poster PresentationbelapectinPresentation
Poster presentation: Risk reduction in clinically significant portal hypertension with belapectin in advanced MASH cirrhosis: results from the NAVIGATE trial
MASH cirrhosissource ↗
May 27, 2026
▲Oral PresentationbelapectinPresentation
Oral presentation at EASL 2026 on belapectin's impact on fibrosis modulation in high-risk MASH cirrhosis
MASH cirrhosissource ↗
May 27, 2026
▲Poster PresentationbelapectinPresentation
Poster presentation at EASL 2026 on risk reduction in clinically significant portal hypertension; designated TOP Poster
MASH cirrhosissource ↗
May 11, 2026
▲Full ResultsbelapectinClinical Data
Publication of NAVIGATE Phase 2b trial results for belapectin in Journal of Hepatology
MASH cirrhosis and portal hypertensionsource ↗
May 2026
◆Oral PresentationbelapectinPresentation
Data presentations at EASL later this month
MASH cirrhosis and portal hypertensionsource ↗
Q2 2026
◆Type C MeetingbelapectinFDA Meeting
In-person Type-C meeting with FDA to align on next steps for belapectin program
MASH cirrhosissource ↗
Drug Pipeline Intelligence
D38
Pipeline Score $19M
Pipeline ValueRichly Valued
Valuation Signal4
Drugs Scored0.1x
rNPV / MCap Top 54%
Micro Cap (rank 420 of 911)
Percentile RankGalectin Therapeutics Inc. faces pipeline headwinds (38/100), with $1.4B risk-adjusted pipeline value, led by GR-MD-02 in Psoriasis (Phase 2), across $85B in total addressable markets.
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| GR-MD-02 Small molecule | Nonalcoholic Steatohepatitis | Phase 2 | NCT02421094 | 21% | $960M | COMPLETED | 30 | - | - | Sep 27, 2016 | - | Oct 8, 2020 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
belapectin Fast Track | advanced MASH cirrhosis | — | 2026-05-27 | p=0.04; 11.7% vs. 23.9%; p=0.03; p=0.0073 | Galectin Therapeutics Presents New EASL 2026 Oral and Poster Analyses Demonstrating Belapectin’s Potential to Modify Disease Progression in Advanced MASH Cirrhosis Read More | |
belapectin Fast Track | advanced MASH cirrhosis | — | 2026-05-27 | p=0.04; 11.7% vs. 23.9%; p=0.03; p=0.0073 | Galectin Therapeutics Presents New EASL 2026 Oral and Poster Analyses Demonstrating Belapectin’s Potential to Modify Disease Progression in Advanced MASH Cirrhosis Read More | |
belapectin Fast Track | advanced MASH cirrhosis | — | 2026-05-27 | p=0.04; 11.7% vs. 23.9%; p=0.03; p=0.0073 | Galectin Therapeutics Presents New EASL 2026 Oral and Poster Analyses Demonstrating Belapectin’s Potential to Modify Disease Progression in Advanced MASH Cirrhosis Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in GALT
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
GALT Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-08-21 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-08-21 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-08-21 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
GALT▲ +11.4%on this news· ran to +78% by day 3
Galectin Therapeutics Announces Positive Type C Meeting with the FDA for Belapectin in Patients with MASH Cirrhosis and Portal Hypertension
Galectin Therapeutics announced a positive Type C meeting with the FDA regarding belapectin for treating MASH cirrhosis and portal hypertension. The FDA agreed on the primary endpoint and regulatory pathway for a Phase 3 trial, which is set to be filed in Q3 2026. The trial aims to assess the drug's efficacy in preventing disease progression, addressing significant unmet medical needs in this patient population.
Read more →GALTGalectin Therapeutics Presents New EASL 2026 Oral and Poster Analyses Demonstrating Belapectin’s Potential to Modify Disease Progression in Advanced MASH Cirrhosis
Galectin Therapeutics presented new findings at EASL 2026 regarding belapectin's efficacy in modifying disease progression in patients with advanced MASH cirrhosis. The NAVIGATE trial data demonstrated that belapectin significantly reduces the development of varices and improves liver stiffness. The poster presentation was recognized as a TOP Poster, underscoring its importance in the field.
Read more →GALT▼ -7.7%on this news
Galectin Therapeutics Reports March 31, 2026 Financial Results and Provides Business Update
Galectin Therapeutics reported its Q1 2026 financial results, highlighting advancements in the belapectin program for MASH cirrhosis. The NAVIGATE trial showed promising data, with significant reductions in liver stiffness. The company is preparing for upcoming presentations at the EASL congress and a Type-C meeting with the FDA. Despite a net loss, Galectin has sufficient cash to fund operations through mid-2027.
Read more →GALT▼ -7.7%on this news
Galectin Therapeutics Reports
Galectin Therapeutics reported its financial results for Q1 2026, highlighting advancements in its belapectin program targeting MASH cirrhosis. The company presented encouraging data supporting the drug's potential efficacy, and it is preparing for significant upcoming data presentations and an FDA meeting. Despite these positive developments, Galectin faces challenges, including ongoing operating losses and the uncertainties inherent to clinical trials. The company's focus remains on establishing partnerships and securing further funding to advance its pipeline.
Read more →GALT▲ +5.2%on this news
Galectin Therapeutics Announces Publication of NAVIGATE Phase 2b Trial Results for Belapectin in the Journal of Hepatology
Galectin Therapeutics has published results from its NAVIGATE Phase 2b trial of belapectin, demonstrating a numerical reduction in new esophageal varices in patients with MASH cirrhosis and portal hypertension. The study showed statistically significant results in the per-protocol population, alongside favorable safety and tolerability. These findings support the continued development of belapectin as a potential treatment for this patient population.
Read more →GALTGalectin Therapeutics, Inc. Investigated by the Portnoy Law Firm
Galectin Therapeutics, Inc. is under investigation by the Portnoy Law Firm for potential securities fraud following a substantial drop in stock price. The decline, which saw shares fall by 28.9%, was triggered by adverse regulatory news regarding their primary drug, belapectin. The U.S. FDA's change in engagement from direct discussions to written responses amidst unresolved trial design elements has raised significant investor concerns. The law firm is seeking to represent investors who suffered losses due to these issues.
Read more →GALT▲ +8.6%on this news
Galectin Therapeutics Reports 2025 Financial Results and Provides Business Update
Galectin Therapeutics reported its 2025 financial results, highlighting advancements in the belapectin program. The company is encouraged by findings from the NAVIGATE dataset related to MASH cirrhosis and portal hypertension. Financially, Galectin secured a $10 million line of credit to extend its cash runway through April 2027. The company anticipates an FDA meeting to discuss the program's future.
Read more →GALTGalectin Therapeutics Strengthens Board of Directors with Appointment of Henry Brem, M.D.
Galectin Therapeutics has appointed Dr. Henry Brem as an independent director to its Board of Directors. Dr. Brem is a renowned neurosurgeon-scientist with significant experience in translational medicine. His expertise is expected to support Galectin's strategic priorities, particularly in advancing their lead drug, belapectin, for MASH cirrhosis and portal hypertension.
Read more →GALTGalectin Therapeutics to Host Virtual KOL Event to Discuss Belapectin Development Program for Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) Cirrhosis and Portal Hypertension, on March 10, 2026 at 12:00 PM ET
Galectin Therapeutics Inc. announced a virtual key opinion leader (KOL) event scheduled for March 10, 2026, to discuss the development of belapectin for treating metabolic dysfunction-associated steatohepatitis (MASH) cirrhosis and portal hypertension. The event will highlight significant findings from the NAVIGATE Phase 3 clinical trial, which emphasize belapectin's antifibrotic and disease-modifying capabilities. This development comes at a critical time given the lack of approved therapies for managing varices in MASH cirrhosis.
Read more →GALT▼ -8%on this news
Galectin Therapeutics Provides Regulatory Update Following FDA Written Response and Announces an Additional $10 Million Line of Credit from Richard E. Uihlein Sufficient to Cover Expected Expenditures Through March 2027
Galectin Therapeutics has received a written response from the FDA regarding its development program for belapectin, indicating alignment on the proposed patient population for a registration trial. The company plans to hold a follow-up Type C meeting to finalize clinical trial design and present new biomarker data. Additionally, Galectin has secured a $10 million line of credit to support its operations through March 2027.
Read more →GALTThanks Kevin, Since I became President and CEO of Galectin Therapeutics, I can honestly say that I have never been as excited as I am today, nor have I had the luxury of sharing such an extensive amount of meaningful inf
Galectin Therapeutics has announced exciting developments as the company trades near multi-year highs. The CEO expressed gratitude towards the team and KOLs for their contributions to the NAVIGATE trial, which is generating promising results, particularly regarding belapectin's impact on patients with compensated MASH cirrhosis and portal hypertension. Key findings from the trial indicate potential benefits in reducing disease progression and improving clinical outcomes. The company is actively enhancing its data presentation and exploring strategic opportunities moving forward.
Read more →GALTGalectin Therapeutics Reports Financial Results for the quarter ended
Galectin Therapeutics reported its financial results for the quarter ending September 30, 2025, highlighting promising data from its NAVIGATE trial for belapectin. The results indicate encouraging consistency across key biomarkers related to the drug's antifibrotic activity in patients with compensated MASH cirrhosis. The company is anticipating FDA guidance on next steps and seeks to improve its development programs amid persistent operating losses. Despite financial challenges, the advancements in belapectin's clinical profile suggest potential for impactful treatment in chronic liver disease.
Read more →GALTGalectin Therapeutics Presented NAVIGATE Trial Results at the American Association for the Study of Liver Diseases (AASLD) 2025 Annual Meeting
Galectin Therapeutics presented promising results from the Phase 2 NAVIGATE trial at the AASLD 2025 Annual Meeting. The trial evaluated belapectin, a galectin-3 inhibitor, in patients with compensated MASH cirrhosis and portal hypertension. Results indicated a significant reduction in the incidence of new varices and improvements in key biomarkers over 36 months, highlighting belapectin's potential as a disease-modifying therapy.
Read more →GALTGalectin Therapeutics to Present at the H.C. Wainwright 9th Annual MASH Investor Conference
Galectin Therapeutics will present at the H.C. Wainwright 9th Annual MASH Investor Conference on October 21, 2025. The management team, including CEO Joel Lewis and CMO Khurram Jamil, will also hold one-on-one meetings with investors. The company focuses on therapies for chronic liver disease and cancer, with its lead drug belapectin targeting galectin-3.
Read more →GALT▲ +7.4%on this news
Galectin Therapeutics to Present at the American Association for the Study of Liver Disease (AASLD) Liver Meeting 2025
Galectin Therapeutics announced its participation in the AASLD Liver Meeting 2025, where it will present data from the NAVIGATE trial on belapectin, a treatment targeting MASH cirrhosis. The company's findings indicate that belapectin can reduce liver stiffness progression and prevent varices in patients over the trial duration. The meeting will take place from November 7-11, 2025, in Washington, DC, further reflecting the growing interest in therapies addressing MASH cirrhosis. CEO Joel Lewis expressed optimism about the potential impact of belapectin on treatment options for patients suffering from this condition.
Read more →GALTGalectin TherapeuticsCorporate OverviewSeptember 2025 2 This presentation contains, in addition to historical information, forward-looking statements within the meaning of the Private Securities Litigation Reform Act of
Galectin Therapeutics provides an overview of its strategic direction and development plans, highlighting its primary drug, Belapectin, aimed at treating MASH cirrhosis and cancer. The presentation delves into the potential of Belapectin, noting significant efficacy seen in NAVIGATE trial results and Fast Track Designation by the FDA. However, the company also acknowledges risks related to future trial outcomes and its history of operating losses. Galectin Therapeutics aims to contribute significantly to the treatment landscape for chronic liver diseases and cancer with its focus on research, development, and partnerships.
Read more →GALTGalectin Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference
Galectin Therapeutics, Inc. announced its participation in the H.C. Wainwright 27th Annual Global Investment Conference from September 8-10, 2025, in New York. The company will present on September 8, 2025, at 1:00 PM ET, with a live webcast available on their website. Key management will also be available for one-on-one meetings with interested investors. Galectin is focused on developing therapies targeting galectin proteins, with an emphasis on liver disease and cancer treatments.
Read more →GALTGalectin Therapeutics Reports Financial Results for the Quarter Ended June 30, 2025 and Provides Business Update
Galectin Therapeutics reported its financial results for Q2 2025, highlighting encouraging data from the NAVIGATE trial for belapectin in treating MASH cirrhosis. The company noted a significant clinical response and plans to engage with the FDA regarding future steps. Despite positive developments, challenges remain, including financial losses and the need for strategic partnerships.
Read more →GALT▲ +7.7%on this news· ran to +36% by day 3
Galectin Therapeutics Announces New $10 Million Credit Line from Richard E. Uihlein, Sufficient to Cover Expected Expenditures Through June 2026
Galectin Therapeutics has secured a $10 million unsecured credit line from Richard E. Uihlein, ensuring funding for its MASH cirrhosis program through June 2026. CEO Joel Lewis expressed gratitude for Uihlein's continued support, which minimizes shareholder dilution. The company is optimistic about the ongoing NAVIGATE trial and is preparing to present data to the FDA this fall.
Read more →GALT▲ +8.8%on this news· ran to +77% by day 3
Belapectin for MASH Cirrhosis and Portal Hypertension June 2025 Khurram Today's Agenda 01 02 03 04 05 06 Moderator Michael Cozart, LifeSci Consulting Galectin Company Introduction Joel Lewis (CEO & President) Belapectin
Galectin Company is advancing Belapectin, a galectin-3 inhibitor, for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) cirrhosis and related portal hypertension. Notably, Belapectin has demonstrated promising results in the phase 2b NAVIGATE trial, showing significant improvements in portal pressure and the incidence of esophageal varices. The drug addresses a critical unmet need as there are currently no FDA-approved therapies for reversing fibrosis in MASH cirrhosis. The presentation included insights on the target patient landscape and the market opportunity given the rising prevalence of this condition.
Read more →GALTGalectin Therapeutics to Host Virtual KOL Event to Discuss Belapectin for Treatment of MASH Cirrhosis and Portal Hypertension
Galectin Therapeutics will host a virtual KOL event on June 16, 2025, to discuss belapectin's potential in treating MASH cirrhosis and portal hypertension. The event will cover the current treatment landscape and highlight results from the NAVIGATE Phase 3 clinical trial. Experts in the field will present their insights, emphasizing the drug's significance in addressing an unmet medical need.
Read more →GALTGalectin Therapeutics Reports 2024 Financial Results and Provides Business Update NORCROSS, Ga.
Galectin Therapeutics reported encouraging financial results and progress on its lead drug, belapectin, during the first quarter of 2025. The company emphasized the positive feedback it received from the European Association for the Study of the Liver (EASL) regarding belapectin's efficacy in demonstrating clinically significant responses in liver stiffness and the incidence of new varices in patients with MASH-associated liver cirrhosis. With Fast Track Designation from the FDA, Galectin remains optimistic about belapectin becoming a treatment option for this significant unmet medical need.
Read more →GALTGalectin Therapeutics Reports Financial Results for the Quarter Ended March 31, 2025 and Provides Business Update
Galectin Therapeutics reported financial results for Q1 2025, highlighting advancements in the clinical trial of belapectin. The NAVIGATE trial demonstrated significant efficacy in reducing the incidence of new varices and improving liver stiffness metrics. The company remains focused on addressing the unmet medical needs of patients with MASH-associated liver diseases. Despite a net loss reported for the quarter, sufficient funds are available to continue operations through mid-2025.
Read more →GALTGalectin Therapeutics Presented NAVIGATE Trial Results at the European Association for the Study of the Liver (EASL) 2025 Congress
Galectin Therapeutics presented results from the NAVIGATE trial at the EASL 2025 Congress, showcasing the efficacy of belapectin in treating patients with MASH cirrhosis and portal hypertension. In the study, patients receiving belapectin 2 mg/kg showed a significant 49.3% reduction in the incidence of new varices compared to placebo. Additionally, the treatment demonstrated a beneficial effect on liver stiffness. Overall, the findings support the therapeutic potential of belapectin, reinforcing the need for continued development in addressing unmet medical needs.
Read more →GALTGalectin TherapeuticsCorporate OverviewMay 2025 2 This presentation contains, in addition to historical information, forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.
Galectin Therapeutics has provided a corporate overview featuring their pipeline, primarily focusing on their lead product, Belapectin, a galectin-3 inhibitor. The presentation highlights promising interim results from the NAVIGATE trial, which show efficacy in reducing new varices in cirrhotic patients. The company also discusses challenges like potential delays in clinical trials, operational losses, and the necessity of securing partnerships and funding. Emphasizing the significant market opportunity in treating metabolic dysfunction-associated steatohepatitis (MASH), Galectin aims to address a high unmet need in chronic liver diseases and oncology.
Read more →GALTGalectin Therapeutics to Present at the European Association for the Study of the Liver (EASL) 2025 Congress
Galectin Therapeutics is set to present data from its NAVIGATE study at the EASL 2025 congress, emphasizing the significance of its galectin-3 inhibitor, belapectin, for treating MASH cirrhosis. The company aims to advance understanding in liver cirrhosis and is analyzing further biomarker data. The presentation will occur in Amsterdam, further enhancing the visibility of their promising therapeutic developments. However, uncertainties remain regarding the potential outcomes of the NAVIGATE trial and financial sustainability.
Read more →GALTGalectin TherapeuticsCorporate OverviewFebruary 2025 2 This presentation contains, in addition to historical information, forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1
Galectin Therapeutics has provided an overview of its corporate status and forward-looking statements regarding its drug, Belapectin, which is designed as a galectin-3 inhibitor with Fast Track Designation. The presentation outlines both positive therapeutic indicators and significant market opportunities, particularly for MASH cirrhosis and oncology. However, the firm acknowledges numerous factors that could lead to delays or negative outcomes in clinical trials and financial performance. Financial sustainability remains a challenge as the company continues to operate at a loss.
Read more →GALT▲ +8.5%on this news
Galectin Therapeutics Reports Significant Reduction in New Varices with Belapectin in U.S. Patient Population from the NAVIGATE Trial Additional analysis of data from the NAVIGATE trial showed statistically significant 6
Galectin Therapeutics has reported promising results from the NAVIGATE trial, demonstrating a significant 68.1% reduction in the incidence of new varices among U.S. patients with MASH cirrhosis treated with belapectin. Although the overall intent-to-treat population results did not achieve statistical significance, the analysis of completers highlighted the drug's potential. CEO Joel Lewis emphasized the urgent need for new therapies in this patient population. The company plans to continue analyzing trial data and evaluate next steps for belapectin's development.
Read more →GALTThank you, Kevin, and thank you to everyone for joining the call this morning. Please note that certain statements made today are forward looking in nature. Please see the forward-looking statements disclaimer attached t
Galectin Therapeutics announced the successful completion of their NAVIGATE trial, which is a significant achievement for the company. The trial demonstrated that their drug candidate, belapectin, had a favorable clinical effect in patients with cirrhosis related to MASH, outperforming placebo in key endpoints. The company anticipates further analysis of data and plans to share updates with the FDA, aiming to address the substantial unmet medical needs in this indication. Encouragingly, no serious drug-related adverse events were reported, indicating a favorable safety profile for belapectin.
Read more →GALTGalectin TherapeuticsCorporate OverviewJanuary 2025 2 This presentation contains, in addition to historical information, forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 19
Galectin Therapeutics is presenting a corporate overview that includes potential therapeutic benefits of its lead drug, Belapectin, which has received Fast Track Designation. The company indicates promising efficacy in treating MASH cirrhosis and is exploring its use in combination with checkpoint inhibitors in oncology. However, there are notable risks including potential delays in clinical trials and uncertainties in capital fundraising that could affect their future operations and strategies. The management team has significant expertise in drug development, which they hope will guide the company's progress in a challenging market.
Read more →GALTGalectin Therapeutics to Present at the 2025 MASH-TAG Conference
Galectin Therapeutics, Inc. will present the top-line results of its NAVIGATE trial at the 2025 MASH-TAG Conference, focusing on patients with MASH cirrhosis and portal hypertension. The presentation will detail the effectiveness of belapectin, reporting a decrease in varices development among participants. Furthermore, Galectin's leadership plans to hold one-on-one meetings during the JP Morgan Healthcare Conference to engage with stakeholders about the trial results and future efforts. Belapectin, a drug targeting galectin-3, has received Fast Track designation from the FDA, highlighting its potential in treating chronic liver conditions.
Read more →GALT▼ -48%on this news
Galectin Therapeutics Announces Top-Line Results of NAVIGATE Clinical Trial Evaluating Belapectin in Patients with Cirrhotic Portal Hypertension Caused by MASH In the pre-specified per-protocol population, belapectin sho
Galectin Therapeutics announced top-line results from the NAVIGATE clinical trial evaluating belapectin in patients with MASH cirrhosis and portal hypertension. While the trial did not achieve its composite primary endpoint, significant results were observed in the per-protocol population with a notable 48.9% reduction in new varices. The safety profile of belapectin remained comparable to placebo across all cohorts. Galectin Therapeutics plans to provide further clinical updates and analyze additional data from a continued 36-month treatment period in early 2025.
Read more →GALTGalectin Therapeutics Presents Three Abstracts at the American Association for the Study of Liver Diseases (AASLD) 2024 Liver Meeting
Galectin Therapeutics presented three posters on its NAVIGATE trial during the 2024 Liver Meeting organized by the American Association for the Study of Liver Diseases. The trial focuses on patients with MASH cirrhosis and portal hypertension, investigating belapectin for preventing esophageal varices. Key findings reveal a significant portion of patients screened showed incidental varices, highlighting the necessity for better screening practices. The readout for the NAVIGATE trial is projected for December 2024, demonstrating the company's commitment to advancing treatment options in this area.
Read more →GALT▼ -5.2%on this newsshared move
Galectin Therapeutics Reports Financial Results for the Quarter Ended
Galectin Therapeutics reported its financial results for the quarter ending September 30, 2024, highlighting the ongoing NAVIGATE trial of belapectin in patients with MASH cirrhosis. The company aims to address the significant unmet medical need within this patient population. Additionally, Galectin will present data at the upcoming AASLD 2024 meeting, showcasing findings from the belapectin program. The firm continues to navigate operational losses while expressing optimism about its pipeline and upcoming trial results expected in December.
Read more →GALT▼ -5.2%on this newsshared move
Galectin TherapeuticsCorporate OverviewNovember 2024 2 This presentation contains, in addition to historical information, forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1
Galectin Therapeutics presented an overview highlighting forward-looking statements regarding the development of their drug, Belapectin, intended for MASH (metabolic dysfunction-associated steatohepatitis) cirrhosis and oncology applications. The presentation emphasizes the potential benefits of Belapectin, which has received fast-track designation, and outlines ongoing clinical trials, with topline results expected by December 2024. However, it also cautions about various risks including clinical trial delays due to external factors, ongoing operational losses, and challenges in securing financial partnerships.
Read more →GALTGalectin Therapeutics Announces Acceptance of Three Abstracts for the American Association for the Study of Liver Diseases (AASLD) 2024 Liver Meeting
Galectin Therapeutics announced the acceptance of three abstracts for presentation at the upcoming AASLD 2024 Liver Meeting. These abstracts focus on the ongoing Phase 2b/3 NAVIGATE trial, which investigates the use of belapectin in patients with MASH cirrhosis and portal hypertension. The presentations will provide insights into various aspects of the disease, including the characteristics of patients and the evaluation of varices in cirrhotic patients. This recognition at a major conference highlights the company's ongoing commitment to addressing chronic liver diseases.
Read more →GALTGalectin Therapeutics to Participate in the H.C. Wainwright MASH Conference
Galectin Therapeutics, a leader in therapies targeting galectin proteins, announced that CEO Joel Lewis and CMO Khurram Jamil will attend the H.C. Wainwright MASH Investor Conference on October 7, 2024. Dr. Jamil will provide updates on the company's clinical programs and the advancement of its pipeline, particularly focusing on belapectin, a drug with Fast Track designation for treating MASH-related liver cirrhosis. The conference highlights the company's commitment to improving treatment options for chronic liver disease and cancer.
Read more →GALTGalectin TherapeuticsCorporate OverviewAugust 2024 2 This presentation contains, in addition to historical information, forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 199
Galectin Therapeutics has outlined its corporate overview, highlighting its lead asset, belapectin, a galectin-3 inhibitor with Fast Track designation. The company aims to address metabolic dysfunction-associated steatohepatitis (MASH) and several difficult-to-treat cancers, with encouraging preclinical data supporting its potential. Despite a solid cash position projected through May 2025, the company acknowledges risks related to trial delays and the need for successful partnerships to continue progressing. Overall, belapectin represents a unique opportunity in a market lacking FDA-approved treatments for MASH cirrhosis.
Read more →GALT▼ -7.2%on this news
Galectin Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference
Galectin Therapeutics, Inc. (NASDAQ: GALT) announced its participation in the H.C. Wainwright 26th Annual Global Investment Conference from September 9-11, 2024. CEO Joel Lewis and CMO Khurram Jamil will represent the company, with Dr. Jamil scheduled to present on September 9. Additionally, Galectin management will be available for one-on-one meetings with investors. The firm focuses on developing innovative therapies for chronic liver disease and cancer, with its lead drug, belapectin, receiving Fast Track designation from the FDA for MASH-related fibrosis.
Read more →GALT▼ -10.6%on this news
Galectin Therapeutics Appoints Khurram Jamil, M.D. to Chief Medical Officer NORCROSS, Ga.
Galectin Therapeutics has appointed Dr. Khurram Jamil as the new Chief Medical Officer, effective immediately. Jamil brings over 20 years of experience in liver disease and has been part of the company since March 2024. He is expected to lead the NAVIGATE clinical trial of belapectin, which aims to address metabolic dysfunction-associated steatohepatitis (MASH) with cirrhosis, an area of significant medical need. The company anticipates interim analysis results in December 2024.
Read more →GALTGalectin Therapeutics to Present at the European Association for the Study of the Liver (EASL) 2024 Congress
Galectin Therapeutics Inc. announced its participation in the EASL 2024 Congress, where it will present scientific findings related to liver cirrhosis and portal hypertension. The data highlights the shortcomings of liver biopsies in assessing liver health, supporting the use of endoscopies as a safer alternative. The company aims to emphasize the importance of early detection and treatment of portal hypertension, which can significantly benefit patients. Their lead drug, belapectin, is aimed at addressing the pressing medical need in this area.
Read more →GALTGalectin Therapeutics to Participate in the H.C. Wainwright BioConnect Conference
Galectin Therapeutics Inc. will participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference set for May 20, 2024. During the conference, a fireside chat will feature the Galectin management team, who will also be available for one-on-one meetings with investors. The company is noted for its commitment to developing treatments for chronic liver disease and cancer, particularly with its lead drug belapectin, which targets the galectin-3 protein.
Read more →GALT▲ +5.3%on this news
Galectin Therapeutics Reports the Positive Outcome of the Fifth Data and Safety Monitoring Board Meeting for NAVIGATE Phase 2b/3 Study of Belapectin in Patients with Cirrhotic Portal Hypertension Caused by Metabolic Dysfunction-Associated SteatoHepatitis
Galectin Therapeutics reported a positive outcome from the fifth Data and Safety Monitoring Board meeting, recommending the continuation of the NAVIGATE Phase 2b/3 study of belapectin for patients with cirrhotic portal hypertension due to metabolic dysfunction-associated steatohepatitis. The DSMB's review indicates that belapectin maintains a favorable safety and tolerability profile, and the next interim analysis is anticipated in Q4 2024. This study represents a significant potential advancement in cirrhosis treatment, with hopes that it may positively impact clinical outcomes for these patients.
Read more →GALTGalectin Therapeutics Reports 2023 Financial Results and Provides Business Update NORCROSS, Ga.
Galectin Therapeutics has announced its 2023 financial results and provided an update on its business progress, particularly regarding the belapectin program targeting liver cirrhosis. The CEO highlighted the completion of enrollment for the NAVIGATE Phase 2b/3 trial, which is expected to provide its interim analysis in Q4 2024. The company has received a $10 million credit facility to support its continued operations as it develops new treatment options for patients with metabolic dysfunction-associated steatohepatitis. Despite achieving operational milestones, the company faces ongoing financial challenges and risks associated with clinical trials.
Read more →GALTGalectin Therapeutics Expands Clinical Team with the Appointment of Khurram Jamil, M.D. as Vice President, Clinical Development
Galectin Therapeutics has appointed Dr. Khurram Jamil as Vice President of Clinical Development. Dr. Jamil has nearly 20 years of experience in biotechnology, specifically in clinical development for hepatology and liver cirrhosis. His role will be vital as the NAVIGATE Phase 2b/3 trial of belapectin progresses, with interim results expected by late 2024. Galectin aims to leverage his expertise to advance its treatment offerings for serious liver diseases and cancer.
Read more →GALTThanks Kevin and thank you to everyone joining us today. Please note that certain statements made today are forward looking in nature. Please see the forward-looking statements disclaimer attached to the Agenda for the A
Galectin Therapeutics provided insights into its development programs during an annual meeting, emphasizing its unique position in the NASH landscape. The company has made significant strides in the NAVIGATE clinical trial, achieving positive outcomes that strengthen confidence in its treatment, belapectin. With an interim analysis expected in the coming year, Galectin is preparing for strategic advancements, including the recruitment of new team members and enhancing communication with stakeholders. Additionally, Dr. Ben Carson has joined the Board, which may bolster the company's efforts moving forward.
Read more →GALTGalectin Therapeutics to Share Five Scientific Presentations at The Liver Meeting™ 2023, Hosted by the AASLD
Galectin Therapeutics announced it will present five scientific abstracts at The Liver Meeting 2023, focusing on belapectin, its lead drug for liver cirrhosis associated with NASH. The presentations will cover important aspects such as pharmacokinetics, safety, and biomarkers related to liver disease. Notably, belapectin has demonstrated a favorable safety profile and could potentially reverse liver damage. The event will showcase new insights into liver cirrhosis, highlighting the importance of early diagnosis and intervention in affected patients.
Read more →GALTGalectin Therapeutics to Participate in the H.C. Wainwright 7th Annual NASH Investor Conference on October 24, 2023
Galectin Therapeutics Inc. is set to present at the H.C. Wainwright 7th Annual NASH Investor Conference on October 24, 2023. Dr. Pol F. Boudes, the Chief Medical Officer, will explain recent advancements in the company's lead drug, belapectin. Preclinical studies have indicated that belapectin could effectively reverse liver fibrosis in patients with NASH-related cirrhosis, with further clinical trials underway to evaluate its efficacy. The NAVIGATE trial is particularly noteworthy as it aims to assess belapectin's ability to prevent esophageal varices in NASH cirrhosis patients, with results expected in late 2024.
Read more →GALTGalectin Therapeutics Announces Nomination of Dr. Benjamin S. Carson, Sr. to Board of Directors
Galectin Therapeutics has nominated Dr. Benjamin S. Carson, Sr. to its board of directors, where he aims to leverage his extensive medical and scientific knowledge for the company's ongoing clinical projects. Dr. Carson has been a senior advisor to Galectin since 2021, contributing to the company's NAVIGATE trial focused on NASH-related cirrhosis. His nomination is set to be finalized during the upcoming annual stockholders meeting on December 7, 2023, as the company advances its research on belapectin, a potential treatment for liver cirrhosis. Galectin Therapeutics seeks to develop novel therapies targeting chronic liver diseases and cancer.
Read more →GALTGalectin Therapeutics Reports the Positive Outcome of the Fourth Data and Safety Monitoring Board Meeting for NAVIGATE, its Seamless, Adaptive Phase 2b/3 Study of Belapectin in Patients with Portal Hypertension Caused by Non-Alcoholic SteatoHepatitis Liver Cirrhosis
Galectin Therapeutics has announced a positive outcome from the fourth Data and Safety Monitoring Board (DSMB) meeting for its NAVIGATE study, which investigates belapectin for patients with portal hypertension due to non-alcoholic steatohepatitis liver cirrhosis. The DSMB concluded that the study can continue without changes, highlighting its strong safety profile. Interim data from the Phase 2b segment is expected in Q4 2024, as researchers aim to better develop therapies for liver cirrhosis, a condition with no currently approved drug treatments.
Read more →GALTGalectin Therapeutics to Present Update on its Belapectin Liver Cirrhosis Program at the 20th Edition of Discovery on Target meeting, in Boston, September 25-28, 2023
Galectin Therapeutics, Inc. will present an update on its belapectin liver cirrhosis program at the Discovery on Target meeting in Boston. The presentation, led by Chief Medical Officer Dr. Pol F. Boudes, will highlight the role of activated macrophages in liver cirrhosis and the therapeutic potential of belapectin, a galectin-3 inhibitor. Preclinical data suggest that belapectin may significantly impact the treatment of liver fibrosis and cirrhosis. Additionally, the NAVIGATE trial is underway to assess belapectin's efficacy in preventing esophageal varices in patients with NASH cirrhosis.
Read more →GALT▲ +6.7%on this news
Galectin Therapeutics to Participate in the H.C. Wainwright 25th Annual Global Investment Conference on September 13, 2023
Galectin Therapeutics Inc. announced its participation in the H.C. Wainwright 25th Annual Global Investment Conference on September 13, 2023. Dr. Pol F. Boudes, the Chief Medical Officer, will present insights on the company's lead drug, belapectin, a therapeutic targeting galectin-3 for treating liver cirrhosis and advanced cancers. The conference serves as a platform for networking and investment opportunities, aligning with the company's ongoing initiatives in developing novel therapies for chronic liver disease and cancer. The upcoming NAVIGATE trial's expectations reflect the company’s focus on strong clinical outcomes with belapectin.
Read more →GALT▲ +7.3%on this newsshared move
Galectin Therapeutics to Present Data on Liver Cirrhosis at the 9th Edition of the Paris NASH meeting, at Institut Pasteur, September 7th & 8th 2023
Galectin Therapeutics Inc. is set to present data on liver cirrhosis at the 9th Paris NASH meeting. They will showcase research on the role of artificial intelligence in assessing liver tissue histology related to non-alcoholic steatohepatitis (NASH) and highlight the clinical significance of their treatment candidate, belapectin. The presentation aims to outline innovative methodologies for evaluating outcomes in NASH cirrhosis, particularly regarding esophageal varices. The data presented will contribute to ongoing discussions about the future of treatments for this condition.
Read more →GALTGalectin Therapeutics to Participate in the H.C. Wainwright BioConnect Investment Conference May 2, 2023
Galectin Therapeutics announced its participation in the H.C. Wainwright BioConnect Investment Conference on May 2, 2023. CEO Joel Lewis and CMO Dr. Pol F. Boudes will discuss their NAVIGATE trial, which evaluates the efficacy of belapectin for preventing esophageal varices in patients with NASH cirrhosis. This trial completed patient randomization in February 2023 and is significant as it may lead to the first approved therapy for this condition. The company aims to address the growing need for effective treatments in a disease that currently has no approved drug therapies.
Read more →GALTGalectin Therapeutics’ Statement Following the Recent 2023 Emerging Topic Conference on NASH Cirrhosis, Sponsored by the American Association for the Study of Liver Diseases
Galectin Therapeutics Inc. attended the 2023 Emerging Topic Conference on NASH Cirrhosis in Los Angeles, focusing on innovative approaches to managing this critical health issue. The conference emphasized the challenges in treating liver cirrhosis and highlighted Galectin's NAVIGATE study, which evaluates belapectin as a preventive treatment for esophageal varices in patients with portal hypertension due to NASH. Insights were shared regarding the limitations of contemporary study designs and the need for new therapeutic options, particularly as projections indicate a rising number of cases. Galectin aims to address this urgent need through its ongoing clinical development efforts.
Read more →GALTGalectin Inhibitors Drugs Companies Clinical Trials Insight 2023
The article discusses the evolving landscape of galectin inhibitors and their potential therapeutic applications, particularly in cancer. It highlights the significant increase in research regarding galectins over the past two decades, positioning them as a promising target for drug development. While some companies, like Galectin Therapeutics, are advancing the clinical pipeline with drug candidates such as GB1211, challenges remain in proving their efficacy and gaining broader pharmaceutical interest. The market for galectin inhibitors is still developing, but future opportunities are anticipated as their potential becomes more recognized.
Read more →GALT▲ +5.3%on this news
Galectin Therapeutics Reports 2022 Financial Results and Provides Business Update NORCROSS, Ga.
Galectin Therapeutics reported its financial results for 2022, showing a net loss of $38.9 million, up from $30.7 million in 2021. The company provided updates on its Phase 2b/3 NAVIGATE trial for preventing esophageal varices in NASH cirrhosis, having randomized 357 patients. The trial has received a positive evaluation from the Data Safety Monitoring Board, and interim analysis results are anticipated by Q4 2024. Additionally, Galectin is exploring a Phase 2 clinical trial combining belapectin with Keytruda for advanced head and neck cancers.
Read more →GALTGalectin Therapeutics Reports the Positive Outcome of the Third Data and Safety Monitoring Board Meeting for NAVIGATE, its Seamless, Adaptive Phase 2b/3 Study of Belapectin in Patients with Liver Cirrhosis Caused by Non-Alcoholic Steatohepatitis
Galectin Therapeutics announced a positive outcome from its third Data and Safety Monitoring Board (DSMB) meeting for the NAVIGATE study, which is assessing the efficacy of belapectin in patients with liver cirrhosis due to non-alcoholic steatohepatitis (NASH). The DSMB concluded that the trial can continue without modifications, reinforcing confidence in belapectin's safety and efficacy. Interim results from the Phase 2b portion are expected in the fourth quarter of 2024, making this a crucial milestone for both the company and patients affected by this condition. The outcome highlights the pressing need for new therapeutic options as liver transplantation remains a complex and scarce solution.
Read more →GALT▲ +8.3%on this news
Galectin Therapeutics Provides Final Randomization Status of NAVIGATE, its Seamless, Adaptive Phase 2b/3 Study of Belapectin in Patients with Liver Cirrhosis Caused by Non-Alcoholic Steatohepatitis NORCROSS, Ga.
Galectin Therapeutics announced the completion of patient randomization in its NAVIGATE study, which is aimed at evaluating the efficacy of belapectin in patients with liver cirrhosis caused by non-alcoholic steatohepatitis (NASH). The final count reached 357 participants, surpassing the initial recruitment target. This study is notable for focusing on the prevention of esophageal varices in patients already experiencing portal hypertension due to cirrhosis. Results from the interim analysis are expected by the fourth quarter of 2024, marking a significant milestone in potentially developing treatments for this condition.
Read more →GALTGalectin Therapeutics contribution to improve histology interpretation of cirrhotic liver biopsies with Machine Learning published in prominent Gastroenterology Journal
Galectin Therapeutics Inc. announced the publication of a scientific paper in Alimentary Pharmacology and Therapeutics, which discusses a machine learning-based model for evaluating liver biopsies. This study analyzes data from a phase 2 clinical trial related to nonalcoholic steatohepatitis cirrhosis. The innovative technology aims to improve the interpretation of liver histology, potentially leading to better treatment outcomes. However, results are preliminary and require further validation in various datasets.
Read more →GALT▼ -5%on this news
Galectin Therapeutics Announces the End of Enrollment of NAVIGATE, its Seamless, Adaptive Phase 2b/3 Study of Belapectin in Patients with Liver Cirrhosis Caused by Non-Alcoholic Steatohepatitis NORCROSS, Ga.
Galectin Therapeutics announced the completion of patient enrollment for its NAVIGATE study, focused on belapectin for treating liver cirrhosis related to non-alcoholic steatohepatitis (NASH). The study, which aims to prevent the progression to esophageal varices, involved 309 patients from 14 countries and is expected to reach a final total of 325 to 340 participants. Interim results from the trial are anticipated in the fourth quarter of 2024, marking a significant step forward in the clinical development of belapectin.
Read more →GALTThanks Kevin, and thank you to everyone joining us today. Out of an abundance of caution, management and the Board made the decision to hold our meeting virtually due to uncertainty surrounding Covid-19 at the time of pl
Thanks Kevin, and thank you to everyone joining us today. Out of an abundance of caution, management and the Board made the decision to hold our meeting virtually due to uncertainty surrounding Covid-19 at the time of planning the meeting. Please note that certain statements mad
Read more →GALTGalectin Therapeutics to Webcast Corporate Update on December 1, 2022 after Annual Meeting of Stockholders
NORCROSS, Ga., Nov. 29, 2022 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc.(NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, announced today that management will present a corporate update via live webcast immediately following the business porti
Read more →GALTGalectin Therapeutics to Present at 6th Obesity & NASH Drug Development Summit
NORCROSS, Ga., Nov. 28, 2022 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, announced today the Company will be presenting at the 6th Obesity and NASH Drug Development Summit in Boston, MA. On N
Read more →GALTGalectin Therapeutics to Share Five Scientific Presentations at The Liver Meeting™ 2022, Hosted by the AASLD
Prevalence of esophageal and gastric varices in patients with compensated NASH cirrhosis and portal hypertension Biochemical and imaging profiles in 271 patients with compensated NASH cirrhosis and portal hypertension Hepatic Expression of Galectin-3, a Pro-fibrotic and Pro-inf
Read more →GALT▲ +5.2%on this news
Galectin Therapeutics to Present in Upcoming Conferences
NORCROSS, Ga., Oct. 14, 2022 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, announced today the Company will be presenting at two upcoming conferences. On October 17, 2022, management will prese
Read more →GALTGalectin Therapeutics Receives FDA Approval to Proceed with Combination Immunotherapy Trial in Head and Neck Cancer NORCROSS, Ga.
Galectin Therapeutics Receives FDA Approval to Proceed with Combination Immunotherapy Trial in Head and Neck Cancer NORCROSS, Ga., October 12, 2022 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin-3, today
Read more →GALTGalectin Therapeutics Reports the Positive Outcome of the Second Data and Safety Monitoring Board Meeting for NAVIGATE, its Seamless, Adaptive Phase 2b/3 Study of Belapectin in Patients with Liver Cirrhosis Caused by Non
Galectin Therapeutics Reports the Positive Outcome of the Second Data and Safety Monitoring Board Meeting for NAVIGATE, its Seamless, Adaptive Phase 2b/3 Study of Belapectin in Patients with Liver Cirrhosis Caused by Non-Alcoholic Steatohepatitis NORCROSS, Ga., October 6, 2022
Read more →GALT▲ +5.6%on this news
Galectin Therapeutics to Participate in the H.C. Wainwright 24th Annual Global Investment Conference September 13, 2022
NORCROSS, Ga., Sept. 08, 2022 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, announced today the Company will be participating in the H.C. Wainwright 24th Annual Global Investment Conference bein
Read more →GALTGalectin Therapeutics Announces $60 Million Credit Line from Richard E. Uihlein Sufficient to Cover Expected Expenditures Through 2024 NORCROSS, Ga.
Galectin Therapeutics Announces $60 Million Credit Line from Richard E. Uihlein Sufficient to Cover Expected Expenditures Through 2024 NORCROSS, Ga., July 26, 2022 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target
Read more →GALTGalectin Therapeutics Announces 2 Liver Cirrhosis Scientific Presentations at the EASL International Liver Congress™ 2022
NORCROSS, Ga., June 21, 2022 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin-3, announced today two scientific presentations regarding the use of artificial intelligence to analyze liver biopsies of patient
Read more →GALTGalectin Therapeutics to Present in Upcoming H.C. Wainwright Global Investment Conference and the 5th Global NASH Congress
NORCROSS, Ga., May 23, 2022 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, announced today the Company will be presenting at the H.C. Wainwright Global Investment Conference being held from May 2
Read more →GALT▲ +10.1%on this news
Galectin Therapeutics Reports the Positive Outcome of the First Data and Safety Monitoring Board for NAVIGATE, its Seamless, Adaptive Phase 2b/3 Study of Belapectin in Patients with Liver Cirrhosis Caused by Non-Alcoholi
Galectin Therapeutics Reports the Positive Outcome of the First Data and Safety Monitoring Board for NAVIGATE, its Seamless, Adaptive Phase 2b/3 Study of Belapectin in Patients with Liver Cirrhosis Caused by Non-Alcoholic Steatohepatitis NORCROSS, Ga., April 14, 2022 (GLOBE NEW
Read more →GALT▼ -5.8%on this news
Galectin Therapeutics Reports 2021 Financial Results and Provides Business Update NORCROSS, Ga.
Galectin Therapeutics Reports 2021 Financial Results and Provides Business Update NORCROSS, Ga., March 31, 2022 (GLOBE NEWSWIRE) - Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results an
Read more →GALTGalectin Therapeutics to Present at the H.C. Wainwright BioConnect Conference
NORCROSS, Ga., Jan. 06, 2022 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, announced today the Company will be participating in the H.C. Wainwright BioConnect Conference being held virtually Jan
Read more →GALTGalectin Therapeutics Announces Closing of $10 Million in Debt Financing from Its Chairman, Richard E. Uihlein NORCROSS, Ga.
Galectin Therapeutics Announces Closing of $10 Million in Debt Financing from Its Chairman, Richard E. Uihlein NORCROSS, Ga., December 21, 2021 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, tod
Read more →GALTGalectin Therapeutics Discusses Corporate Transformation, Progress of NAVIGATE Trial and Outlines Strategy for Potential Phase 2 Cancer Immunotherapy Trial at Annual Meeting
NAVIGATE clinical trial in NASH cirrhosis now underway in all countries originally selected; full enrollment expected by mid-2022 Dr. Chetan Bettegowda, of Johns Hopkins, and Drs. Nishant Agrawal and Ari Rosenberg, both of the University of Chicago Medical Center, engaged to adv
Read more →GALT▼ -6.9%on this news
Thanks Kevin. And thank you to everyone joining us virtually today. Unfortunately, we are still unable to hold our annual meeting in person due to Covid-19. Hopefully, this will not be the case next year. Regardless, I a
And thank you to everyone joining us virtually today. Unfortunately, we are still unable to hold our annual meeting in person due to Covid-19. Hopefully, this will not be the case next year. Regardless, I am grateful that you are listening. Please note that certain statements ma
Read more →GALTGalectin Pharmaceuticals to Present Six Scientific Abstracts at The Liver Meeting™ 2021, Hosted by the AASLD
New data regarding the mechanism of action of belapectin to inhibit galectin-3 Unique pharmacokinetic profile of belapectin in patients with hepatic insufficiency Innovating in Liver Cirrhosis: Belapectin’s NAVIGATE phase 2b/3 study design New data regarding correlation betwee
Read more →GALTGalectin Therapeutics Announces $20 Million Convertible Debt Financing from Its Chairman, Richard E. Uihlein NORCROSS, Ga.
Galectin Therapeutics Announces $20 Million Convertible Debt Financing from Its Chairman, Richard E. NORCROSS, Ga., September 21, 2021 (GLOBE NEWSWIRE) Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced
Read more →GALTThis presentation contains, in addition to historical information, forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements relate to future events or future
Corporate Overview September 2021 NASDAQ: GALT www.galectintherapeutics.com Exhibit 99.1 This presentation contains, in addition to historical information, forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements r
Read more →GALTGalectin Therapeutics, Inc. to Participate in the H.C. Wainwright 23rd Annual Global Investment Conference
NORCROSS, Ga., Sept. 09, 2021 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today announced the Company’s management will present at the H.C. Wainwright 23rd Annual Global Investment Conference.
Read more →GALTGalectin Therapeutics Strengthens Leadership Team with Strategic Hires to Advance Programs in Cancer Immunotherapy and NASH Cirrhosis
NORCROSS, Ga., Aug. 30, 2021 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced that the Company has recently expanded its management team with multiple key leadership appointments, in
Read more →GALTGalectin Therapeutics Announces Positive Top-Line Results from a Phase 1b Clinical Trial Extension of Belapectin in Combination with KEYTRUDA in Advanced Metastatic Melanoma and Head and Neck Cancer Belapectin and KEYTRU
Galectin Therapeutics Announces Positive Top-Line Results from a Phase 1b Clinical Trial Extension of Belapectin in Combination with KEYTRUDA in Advanced Metastatic Melanoma and Head and Neck Cancer NORCROSS, Ga., July 9, 2021 (GLOBE NEWSWIRE) Galectin Therapeutics Inc. (NASDAQ
Read more →GALTD R A F T Galectin Therapeutics Reports Financial Results for the Quarter Ended
Galectin Therapeutics Reports Financial Results for the Quarter Ended March 31, 2021, and Provides Business Update Continued Favorable Developments in both NAVIGATE and Cancer Combination Immunotherapy Trials NORCROSS, Ga., May 17, 2021 (GLOBE NEWSWIRE) Galectin Therapeutics In
Read more →GALTGalectin Therapeutics Reports Financial Results for the Quarter Ended March 31, 2021, and Provides Business Update
NORCROSS, Ga., May 17, 2021 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and provided a business update for the quarter ended March 31, 2021. These results are
Read more →GALTGalectin Therapeutics to Present at 4th Global NASH Congress
NORCROSS, Ga., April 27, 2021 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced that Pol F. Boudes, M.D., Chief Medical Officer, will present the belapectin program at the 4th Global
Read more →GALTGalectin-3 has a key role in Gastric Cancer
BOSTON, April 15, 2021 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a NASDAQ listed biotechnology company focused on the development of novel treatments for fibrosis and cancer, today announced the publication of a paper in Gastric Cancer, a joint official peer-reviewed jour
Read more →GALTGalectin Therapeutics Launches NAVIGATEnash.com, a Resource for Both Patients and Physicians about its Innovative NASH Cirrhosis Study
NORCROSS, Ga., April 06, 2021 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced the launch of NAVIGATEnash.com, its dedicated trial website. The new website intends to educate patient
Read more →GALTGalectin Therapeutics Reports Fiscal 2020 Financial Results and Provides Business Update NORCROSS, Ga.
Galectin Therapeutics Reports Fiscal 2020 Financial Results and Provides Business Update Ga. March 31, 2021 Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and provided a business u
Read more →GALTGalectin Therapeutics to Present at H.C. Wainwright Global Life Sciences Conference
NORCROSS, Ga., March 04, 2021 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced that Dr. Pol Boudes, M.D., Chief Medical Officer, will provide a corporate overview at the upcoming H.C
Read more →GALTGalectin Therapeutics, Inc. to Present at the 4th Annual Digital NASH Summit on December 17, 2020
NORCROSS, Ga., Dec. 11, 2020 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced that Pol F. Boudes, M.D., Chief Medical Officer, has been invited to make a presentation, entitled “Bela
Read more →GALTGalectin Therapeutics Inc. Recaps Results of Annual Meeting of Stockholders Presentation
NORCROSS, Ga., Dec. 04, 2020 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced the passing of the two items on the Agenda for the 2020 Annual Meeting of Stockholders, that being the e
Read more →GALTThanks Kevin. I want to thank Jack and Beth for putting together our virtual annual meeting, and to all those joining us on the call, I appreciate your participation today. Since we cannot be in Atlanta together, I wante
I want to thank Jack and Beth for putting together our virtual annual meeting, and to all those joining us on the call, I appreciate your participation today. Since we cannot be in Atlanta together, I wanted to personally welcome and wish you a joyous, and most importantly, a he
Read more →GALTGalectin Therapeutics to Webcast Corporate Update on December 3, 2020 after Annual Meeting of Stockholders
NORCROSS, Ga., Dec. 01, 2020 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, announced today that management will present a corporate update via live webcast immediately following the business port
Read more →GALTGalectin Therapeutics Provides Business Update And Reports Financial Results for the Quarter Ended
Galectin Therapeutics Provides Business Update And Reports Financial Results for the Quarter Ended September 30, 2020 Innovative Phase 2b/3 NASH-RX Trial in NASH Cirrhosis Initiated Board Member Joel Lewis Assumes CEO Role Board Adds Two New Highly Accomplished Professionals
Read more →GALTGalectin Therapeutics Investor Conference Call and Webinar Taking Place Today
NORCROSS, Ga., Sept. 29, 2020 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, announced that the Company will host an investor conference call and webinar to discuss the Company’s NASH-RX clinical
Read more →GALTGalectin Therapeutics Announces Investor Conference Call and Webinar on
Galectin Therapeutics Announces Investor Conference Call and Webinar on September 29, 2020 Presentation to discuss the details of the newly launched Phase 2b/3 NASH-RX clinical trial; Introduce new CEO and President Joel Lewis NORCROSS, Ga., September 22, 2020 (GLOBE NEWSWIRE)
Read more →GALTGalectin Therapeutics Inc. to Present at the H.C. Wainwright 22nd Annual Global Investment Conference on September 14, 2020
NORCROSS, Ga., Sept. 10, 2020 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced that management will present at the H.C. Wainwright 22nd Annual Virtual Global Investment Conference, o
Read more →GALTGalectin Therapeutics Appoints Joel Lewis as Chief Executive Officer Dr. Harold Shlevin retires as CEO, transitions to role of scientific and business consultant and will remain on the Board Board strengthened in scienti
Galectin Therapeutics Appoints Joel Lewis as Chief Executive Officer Dr. Harold Shlevin retires as CEO, transitions to role of scientific and business consultant and will remain on the Board Board strengthened in scientific expertise with addition of Dr. Elissa Schwartz and in
Read more →GALTGalectin Therapeutics Announces Commencement of patient enrollment of the Adaptively-Designed Phase 2b/3 Trial of Belapectin in NASH Cirrhosis Clinical Trial for patients with NASH cirrhosis who have the highest need for
Galectin Therapeutics Announces Commencement of patient enrollment of the Adaptively-Designed Phase 2b/3 Trial of Belapectin in NASH Cirrhosis Clinical Trial for patients with NASH cirrhosis who have the highest need for Belapectin has previously shown ability to prevent the d
Read more →GALTGalectin Therapeutics Submits Seamless Adaptively-Designed Phase 2b/3 NASH-RX Protocol in NASH Cirrhosis The first patient currently expected to be enrolled in the second quarter of 2020 NORCROSS, Ga.
Galectin Therapeutics Submits Seamless Adaptively-Designed Phase 2b/3 NASH-RX Protocol in NASH Cirrhosis The first patient currently expected to be enrolled in the second quarter of 2020 NORCROSS, Ga., April 30, 2020 (GLOBE NEWSWIRE) Galectin Therapeutics, Inc. (NASDAQ: GALT),
Read more →GALTGalectin Therapeutics Update on the Impact of COVID-19
NORCROSS, Ga., April 02, 2020 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins today provided an update on the impact of the COVID-19 pandemic on the Company and its clinical trial activities. As
Read more →GALTGalectin Therapeutics Reports Fiscal 2019 Financial Results and Provides Business Update Addition of Pol F. Boudes, M.D. as Chief Medical Officer strengthens executive team for launch of Galectin s NASH-RX trial for the
Galectin Therapeutics Reports Fiscal 2019 Financial Results and Provides Business Update Addition of Pol F. Boudes, M.D. as Chief Medical Officer strengthens executive team for launch of Galectin s NASH-RX trial for the prevention of esophageal varices in patients with NASH c
Read more →GALTGalectin Therapeutics Appoints Seasoned Biopharmaceutical Executive Pol F. Boudes, M.D. as Chief Medical Officer Appointment of industry veteran reflects growing confidence in clinical development program for NASH Cirrho
Galectin Therapeutics Appoints Seasoned Biopharmaceutical Executive Pol F. Boudes, M.D. as Chief Medical Officer Appointment of industry veteran reflects growing confidence in clinical development program for NASH Cirrhosis Norcross, GA., February 20, 2020 (GLOBE NEWSWIRE) Gal
Read more →GALTGalectin Therapeutics’ President and CEO Dr. Harold Shlevin to Present at the 3rd Global NASH Congress 2020
NORCROSS, Ga., Feb. 04, 2020 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc.(NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced that Dr. Harold H. Shlevin, the Company’s President and CEO, will present at the 3rd Global NASH Congress
Read more →GALTGalectin Therapeutics’ Phase 2 NASH Cirrhosis Clinical Trial Results on Belapectin (GR-MD-02) Published in Gastroenterology
NORCROSS, Ga., Dec. 09, 2019 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc.(NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced that a paper highlighting the results of its NASH-CX Phase 2 clinical trial in NASH cirrhosis have been p
Read more →GALTGalectin Therapeutics Plans Adaptively Designed Phase 3 NASH-RX Clinical Trial in NASH Cirrhosis
Interim analysis after 12-18 months of treatment to reaffirm phase 2 results, select optimal dosage and sizing and seamlessly roll into Phase 3 stage of NASH-RX Study Dr. Harold Shlevin, CEO, Discusses Plan at Annual Meeting of Stockholders NORCROSS, Ga., Dec. 05, 2019 (GLOBE N
Read more →GALTForward Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements relate to future events or future financial pe
Corporate Update - focused on NASH Cirrhosis Annual Stockholders Meeting December 4, 2019 Exhibit 99.1 Forward Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements
Read more →GALTGalectin Therapeutics to Webcast Corporate Update on
Galectin Therapeutics to Webcast Corporate Update on December 4, 2019 after Annual Meeting of Stockholders NORCROSS, Ga., November 26, 2019 (GLOBE NEWSWIRE) Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, announced
Read more →GALTGalectin Therapeutics to Present at Anti-Fibrotic Drug Development (AFDD) Summit
NORCROSS, Ga., Nov. 18, 2019 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced that Eliezer Zomer, Ph.D., Vice President, Discovery Research and Product Development for Galectin Thera
Read more →GALTGalectin Therapeutics Reports Q3 2019 Financial Results Provides Update on NASH-RX Trial Plan NORCROSS, Ga.
Galectin Therapeutics Reports Q3 2019 Financial Results Provides Update on NASH-RX Trial Plan NORCROSS, Ga. November 12, 2019 Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and pr
Read more →GALTGalectin Therapeutics Reaches Agreement with Siemens Healthineers to Collaborate on NASH and Liver Fibrosis
NORCROSS, Ga., Nov. 11, 2019 (GLOBE NEWSWIRE) -- Today, Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, announced a collaboration agreement with Siemens Healthineers, a global leader in medical technology, in nonalco
Read more →GALTGalectin Therapeutics, Inc. and Providence Cancer Institute Receive Patent on the Use of Belapectin (GR-MD-02) in Cancer Immunotherapy NORCROSS, Ga.
Galectin Therapeutics, Inc. and Providence Cancer Institute Receive Patent on the Use of Belapectin (GR-MD-02) in Cancer Immunotherapy NORCROSS, Ga., September 17, 2019 (GLOBE NEWSWIRE) Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target
Read more →GALTGalectin Therapeutics Reports Q2 2019 Financial Results and Provides Business Update NORCROSS, Ga. (
Galectin Therapeutics Reports Q2 2019 Financial Results and Provides Business Update NORCROSS, Ga. (August 9, 2019) Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and provided a bu
Read more →GALTGALECTIN THERAPEUTICS SUBMITS PHASE 3 NASH-RX PROTOCOL IN NASH CIRRHOSIS TO FDA NORCROSS, Ga. (
GALECTIN THERAPEUTICS SUBMITS PHASE 3 NASH-RX PROTOCOL IN NASH NORCROSS, Ga. (August 5, 2019) Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today announced it has submitted for assessment the Phase 3 protocol for
Read more →GALTGalectin Therapeutics Raises $44.5 Million in Rights Offering and $2.5 Million From Warrant Exercise NORCROSS, Ga. (
Galectin Therapeutics Raises $44.5 Million in Rights Offering and $2.5 Million From Warrant Exercise NORCROSS, Ga. (May 28, 2019) Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today announced its Rights Offering
Read more →GALTGalectin Therapeutics Reports Alternate Price of Common Stock in Rights Offering
NORCROSS, Ga., May 23, 2019 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported the Alternate Price (i.e., the final computed price) of the common stock and related warrant subscribed i
Read more →GALTGalectin Therapeutics Releases Richard E. Uihlein s Open Letter to Stockholders Dated
Galectin Therapeutics Releases Richard E. Uihlein s Open Letter to Stockholders Dated May 10, 2019 NORCROSS, Ga, May 10, 2019 (GLOBE NEWSWIRE) Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today released this op
Read more →GALTGalectin Therapeutics Reports Q1 2019 Financial Results and Provides Business Update
Subscription rights to purchase Galectin Therapeutics, Inc. common shares, with accompanying warrants, mailed to Holders of Record as of April 29. Rights expire at 5:00 PM Eastern on May 23, 2019 Portion of the Net Proceeds of Rights Offering to be used for Phase 3 clinical tri
Read more →GALTGALECTIN THERAPEUTICS INC. ANNOUNCES RECORD DATE, SUBSCRIPTION PRICING
GALECTIN THERAPEUTICS INC. ANNOUNCES RECORD DATE, SUBSCRIPTION PRICING, AND EXPIRATION DATE FOR RIGHTS OFFERING AND EFFECTIVENESS OF ITS REGISTRATION STATEMENT April 15, 2019 (GLOBE NEWSWIRE) Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that
Read more →GALTGalectin Therapeutics to Present at the 2019 H.C. Wainwright Global Life Sciences Conference
NORCROSS, Ga., April 02, 2019 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced that Dr. Harold Shlevin, the Company’s President and Chief Executive Officer, will present at the H.C.
Read more →GALTGalectin Therapeutics Files Registration Statement for Stockholder Rights Offering of Common Stock and Warrants Richard E. Uihlein, Board Chair, expresses interest in investing $20.0 million in the Rights Offering NORCRO
Galectin Therapeutics Files Registration Statement for Stockholder Rights Offering of Common Stock and Richard E. Uihlein, Board Chair, expresses interest in investing $20.0 million in the Rights Offering NORCROSS, Ga. (March 6, 2019) Galectin Therapeutics Inc. (NASDAQ: GALT),
Read more →GALTGalectin Therapeutics Reports Fiscal 2018 Financial Results and Provides Business Update Planning for Phase 3 clinical trial (NASH-RX) nearing completion for GR-MD-02, the first drug to show positive results in a clinica
Galectin Therapeutics Reports Fiscal 2018 Financial Results and Provides Business Update Planning for Phase 3 clinical trial (NASH-RX) nearing completion for the first drug to show positive results in a clinical trial in patients with compensated NASH cirrhosis NORCROSS, Ga.
Read more →GALTGalectin Therapeutics Releases Richard E. Uihlein s Open Letter to Stockholders NORCROSS, Ga. (
Galectin Therapeutics Releases Richard E. Uihlein s Open Letter to Stockholders NORCROSS, Ga. (March 6, 2019) Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today released this open letter to stockholders written
Read more →GALTGalectin Therapeutics to Present at Berenberg NASH Day in New York
NORCROSS, Ga., Feb. 25, 2019 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced that Dr. Harold H. Shlevin, the Company’s President and CEO, will present at Berenberg NASH Day at the B
Read more →GALTGalectin Therapeutics Largest Institutional Shareholder Converts Existing Series B Preferred Stock Into Common Stock Streamlining Its Capital Structure Board Chairman Richard Uihlein extends existing $10 million unsecure
Galectin Therapeutics Largest Institutional Shareholder Converts Existing Series B Preferred Stock Into Common Stock Streamlining Its Capital Structure Board Chairman Richard Uihlein extends existing $10 million unsecured line of credit for two additional years NORCROSS, Ga.
Read more →GALTGalectin Therapeutics Announces Extension of $10 Million Line Credit NORCROSS, Ga. (
Galectin Therapeutics Announces Extension of $10 Million Line Credit NORCROSS, Ga. (December 20, 2018) Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today announced that its $10 million unsecured line of credit e
Read more →GALTGalectin Therapeutics to Present at the 2nd Annual Anti-Fibrotic Drug Development Summit
NORCROSS, Ga., Nov. 19, 2018 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced that Dr. Harold H. Shlevin, the Company’s President and CEO, will present at the 2nd Annual Anti-Fibroti
Read more →GALTGalectin Therapeutics Reports 2018 Third Quarter Financial Results and Provides Business Update NORCROSS, Ga. (
Galectin Therapeutics Reports 2018 Third Quarter Financial Results and Provides Business Update NORCROSS, Ga. (November 13, 2018) Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results fo
Read more →GALTGalectin Therapeutics to Present at The ROTH Capital Battle of the NASH Thrones Investment Conference
NORCROSS, Ga., Oct. 15, 2018 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced that management will participate in the upcoming ROTH Capital Battle of the NASH Thrones Investor Confer
Read more →GALTGalectin Therapeutics to Participate in The ROTH Capital Battle of the NASH Thrones Investment Conference
NORCROSS, Ga., Oct. 15, 2018 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced that management will participate in the upcoming ROTH Capital Battle of the NASH Thrones Investor Confer
Read more →GALTGalectin Therapeutics, Inc. Announces Positive Preliminary Results from Phase 1b Clinical Trial of GR-MD-02 and KEYTRUDA in Advanced Melanoma and Expansion of the Trial Combination immunotherapy of GR-MD-02 and KEYTRUDA
Galectin Therapeutics, Inc. Announces Positive Preliminary Results from Phase 1b Clinical Trial of GR-MD-02 and KEYTRUDA in Advanced Melanoma and Expansion of the Trial NORCROSS, Ga., September 20, 2018 (GLOBE NEWSWIRE) Galectin Therapeutics Inc. (NASDAQ:GALT), the leading de
Read more →GALTGalectin Therapeutics to Present at H.C. Wainwright 20th Annual Global Investment Conference
NORCROSS, Ga., Aug. 28, 2018 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced that Dr. Harold H. Shlevin, the Company’s President and CEO, will present at the H.C. Wainwright 20th Gl
Read more →GALTGalectin Therapeutics Reports 2018 Second Quarter Financial Results and Provides Business Update NORCROSS, Ga. (
Galectin Therapeutics Reports 2018 Second Quarter Financial Results and Provides Business Update NORCROSS, Ga. (August 14, 2018) Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results for
Read more →GALTGalectin Therapeutics Receives Patent for GR-MD-02 Patent for Method and Treatment of Pulmonary Fibrosis
NORCROSS, Ga., June 27, 2018 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, today announced that the Company has received notice of issuance of U.S. Patent Number 9,9
Read more →GALTGalectin Therapeutics Inc. Announces New
Galectin Therapeutics Inc. Announces New CEO NORCROSS, Ga., June 12, 2018 (GLOBE NEWSWIRE) Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced that Harold H. Shlevin, Ph.D., currently the Company s Chief
Read more →GALTGalectin Therapeutics Inc. Announces New CEO
NORCROSS, Ga., June 12, 2018 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced that Harold H. Shlevin, Ph.D., currently the Company’s Chief Operating Officer (COO), has been appointed
Read more →GALTGalectin Therapeutics Inc. Announces Richard E. Uihlein Elected Chairman of the Board
NORCROSS, Ga., June 04, 2018 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, announced today that the directors elected Richard E. Uihlein as Chairman of the Board of Directors. Additionally, Kevin
Read more →GALTGalectin Therapeutics Proceeds to Phase 3 Development of GR-MD-02 for NASH Cirrhosis Following FDA Meeting NORCROSS, Ga.
Galectin Therapeutics Proceeds to Phase 3 Development of GR-MD-02 for NASH Cirrhosis Following FDA Meeting NORCROSS, Ga., May 14, 2018 (GLOBE NEWSWIRE) Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, announced today
Read more →GALTGalectin Therapeutics Reports 2018 First Quarter Financial Results and Provides Business Update NORCROSS, Ga. (
Galectin Therapeutics Reports 2018 First Quarter Financial Results and Provides Business Update NORCROSS, Ga. (May 11, 2018) Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results for the
Read more →GALTGalectin Therapeutics to Present at 2nd Annual NASH Summit 2018
NORCROSS, Ga., April 18, 2018 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced that Peter G. Traber, M.D., the Company’s CEO and CMO, has been selected as an expert speaker and will
Read more →GALTRationale for Galectin-3 Inhibition in NASH Gal-3 is a lectin protein that binds to galactose residues on glycoproteins and is increased in NASH and liver fibrosis/cirrhosis Gal-3 null mice are resistant to NASH and fibr
A multicenter, randomized, double-blind, placebo-controlled trial of Galectin-3 inhibitor (GR-MD-02) for one year in patients with NASH cirrhosis and portal hypertension The NASH-CX Trial 1Naga Chalasani, 2Guadalupe Garcia-Tsao, 3Zachary Goodman, 4Eric Lawitz, 5Manal Abdelmalek
Read more →GALTGalectin Therapeutics Late-Breaker Presentation at The International Liver Congress Reinforces and Extends the Positive Effects of GR-MD-02 in Patients With NASH Cirrhosis
NORCROSS, Ga., April 16, 2018 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today provided highlights from a late-breaker oral presentation at The International Liver Congress™ 2018, European Ass
Read more →GALTGalectin Therapeutics to Present Late-Breaker Oral Presentation at The International Liver Congress 2018
NORCROSS, Ga., April 04, 2018 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, announced today the presentation of a late-breaker oral presentation on Saturday April 14, 2018 at 16:00 CET in the Mai
Read more →GALTGalectin Therapeutics Reports 2017 Financial Results and Provides Business Update NORCROSS, Ga. (
Galectin Therapeutics Reports 2017 Financial Results and Provides Business Update NORCROSS, Ga. (March 29, 2018) Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results for the year ended D
Read more →GALTGalectin Therapeutics to Present at Two International Conferences in March
NORCROSS, Ga., March 09, 2018 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced that Peter G. Traber, M.D., the Company’s CEO and CMO, will participate in two upcoming international
Read more →GALTGalectin Therapeutics to Present at 2nd Annual H.C. Wainwright NASH Investor Conference
NORCROSS, Ga., March 08, 2018 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced that Dr. Harold Shlevin, the Company’s Chief Operating Officer, will present at the 2nd Annual H.C. Wai
Read more →GALTGalectin Therapeutics Announces Record Date and Annual Stockholders Meeting Date for 2018
NORCROSS, Ga., March 05, 2018 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced March 26, 2018 is the record date for the 2018 Annual Meeting of Stockholders to be held on May 22, 201
Read more →GALTGalectin Therapeutics to Present at 30th Annual ROTH Conference
NORCROSS, Ga., Feb. 28, 2018 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced that Peter G. Traber, M.D., the Company’s CEO and CMO, will present at the 30th Annual ROTH Conference o
Read more →GALTGalectin Therapeutics to Present at BIO CEO & Investor Conference
NORCROSS, Ga., Feb. 06, 2018 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced that Peter G. Traber, M.D., the Company’s CEO and CMO, will present at BIO CEO & Investor Conference on
Read more →GALTGalectin Therapeutics Granted Patents in China and Japan that Support NASH and Cancer Immunotherapy Clinical Development Programs
NORCROSS, Ga., Jan. 25, 2018 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins to treat non-alcoholic steatohepatitis (NASH) cirrhosis and cancer, announced today that the company has received two ne
Read more →GALTForward Looking Statements This presentation contains, in addition to historical information, forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements relate
GR-MD-02 for Indication of NASH Cirrhosis NASH-CX Clinical Trial Results San Francisco, CA January 8-11, 2018 NASDAQ: GALT www.galectintherapeutics.com 2017 Galectin Therapeutics | NASDAQ: GALT For more information, see galectintherapeutics.com Exhibit 99.1 Forward Looking Stat
Read more →GALTGalectin Therapeutics Announces $10 Million Credit Line from Richard E. Uihlein Sufficient to Cover Expected Expenditures Into 2019 NORCROSS, Ga.
Galectin Therapeutics Announces $10 Million Credit Line from Richard E. Uihlein Sufficient to Cover Expected Expenditures Into 2019 NORCROSS, Ga., December 19, 2017 (GLOBE NEWSWIRE) Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target gal
Read more →GALTGalectin Therapeutics Provides Corporate Update at Annual Meeting
Dr. Peter Traber, CEO and CMO, reviews results of NASH-CX trial that demonstrated statistically significant and clinically meaningful effects in patients who had NASH cirrhosis but did not have esophageal varices Approximately 50% of all patients with NASH cirrhosis do not have
Read more →GALTGalectin Therapeutics to Webcast Corporate Update at Annual Meeting of Shareholders
NORCROSS, Ga., Dec. 11, 2017 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, announced today that the Company will present a corporate update via live webcast immediately following the business por
Read more →GALTGalectin Therapeutics Announces Results from Phase 2b NASH-CX Trial
Statistically significant and clinically meaningful effects observed in NASH cirrhosis patients without esophageal varices treated with GR-MD-02 Conference Call at 8:30 A.M. ET to Present Top Line Trial Results NORCROSS, Ga., Dec. 05, 2017 (GLOBE NEWSWIRE) -- Galectin Therapeut
Read more →GALTGalectin Therapeutics to Present Results from Phase 2b NASH-CX Trial on December 5, 2017
NORCROSS, Ga., Dec. 04, 2017 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, will issue a press release announcing the results of its Phase 2b NASH-CX trial on Tuesday morning, December 5, 2017. T
Read more →GALTGalectin Therapeutics CEO Peter G. Traber, M.D. Named Chair of the Anti-Fibrotic Drug Development Summit 2017
NORCROSS, Ga., Nov. 13, 2017 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, announced that Peter G. Traber, M.D., the Company's chief executive officer and chief medical officer, has been named th
Read more →GALTCombination Immunotherapy of Pembrolizumab with the Galectin-3 Inhibitor GR-MD-02 Shows Promising Early Results in Treatment of Advanced Melanoma from a Phase 1b Clinical Trial The objective response rate in advanced mel
Combination Immunotherapy of Pembrolizumab with the Galectin-3 Inhibitor GR-MD-02 Shows Promising Early Results in Treatment of from a Phase 1b Clinical Trial The objective response rate in advanced melanoma was 62.5% (five of eight subjects) NORCROSS, Ga. (November 13, 2017
Read more →GALTGalectin Therapeutics Reports 2017 Third Quarter Financial Results and Provides Business Update All 52 weeks of infusions and 100% of the doses have been administered in the NASH Cirrhosis, NASH-CX Phase 2b Clinical Tria
Galectin Therapeutics Reports 2017 Third Quarter Financial Results and Provides Business Update All 52 weeks of infusions and 100% of the doses have been administered in the NASH Cirrhosis, NASH-CX Phase 2b Clinical Trial NASH-CX Phase 2b Clinical Trial Expected to be announce
Read more →GALTGalectin Therapeutics to Present Clinical Data at The Liver Meeting 2017 Demonstrating the Ability of Non-Invasive Test to Identify Clinically Significant Portal Hypertension in Patients with Compensated NASH Cirrhosis
NORCROSS, Ga., Oct. 20, 2017 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, announced today that Dr. Raj Vuppalanchi of Indiana University will present a poster demonstrating the use of vibration-
Read more →GALTGalectin Therapeutics CEO Peter G. Traber, M.D. Named Chair of the Conference for NASH Summit Europe 2017
NORCROSS, Ga., Sept. 25, 2017 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, announced Peter G. Traber, M.D., the Company’s chief executive officer and chief medical officer was named Chair of the
Read more →GALTGalectin Therapeutics Receives Notice of Chinese Allowance to Grant a Key Patent for Composition of Matter for GR-MD-02
NORCROSS, Ga., Sept. 12, 2017 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced that the Company has received a Decision to Grant from the Chinese Patent Office for its patent applic
Read more →GALTGalectin Therapeutics to Present at the Rodman & Renshaw 19th Annual Global Investment Conference
NORCROSS, Ga., Sept. 05, 2017 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced that management will present at the Rodman & Renshaw 19th Annual Global Investment Conference on Tuesda
Read more →GALTClarification: Galectin Therapeutics Reports 2017 Second Quarter Financial Results and Provides Business Update NORCROSS, Ga.
Clarification: Galectin Therapeutics Reports 2017 Second Quarter Financial Results and Provides Business Update NORCROSS, Ga., Aug. 18, 2017 (GLOBE NEWSWIRE) Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, is issuin
Read more →GALTGalectin Therapeutics Reports 2017 Second Quarter Financial Results and Provides Business Update 80% of the patients enrolled have completed all 52 weeks of infusions and 99% of the doses have already been administered i
Galectin Therapeutics Reports 2017 Second Quarter Financial Results and Provides Business Update 80% of the patients enrolled have completed all 52 weeks of infusions and 99% of the doses have already been administered in the NASH Cirrhosis, NASH-CX Phase 2b Clinical Trial N
Read more →GALTGalectin Therapeutics to Present at the Singular Research Summer Conference
NORCROSS, Ga., July 07, 2017 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced that Harold Shlevin, Ph.D., the Company’s chief operating officer, will be presenting on behalf of the C
Read more →GALTGalectin Therapeutics Announces Important Milestones towards Completion of NASH CX Trial
NORCROSS, Ga., June 13, 2017 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis, skin disease, and cancer, announces the independent data safety monitoring board (DSMB) recently concl
Read more →GALTGalectin Therapeutics Reports 2017 First Quarter Financial Results and Provides Business Update NORCROSS, Ga. (
Galectin Therapeutics Reports 2017 First Quarter Financial Results and Provides Business Update NORCROSS, Ga. (May 15, 2017) Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results for the
Read more →GALTGalectin Therapeutics launches the Liver Line, an online community and publication on liver health and liver disease
NORCROSS, Ga., May 03, 2017 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced the launch of the Liver Line, an online community and publication on liver health and liver disease. Liv
Read more →GALTGalectin Therapeutics Receives Notice of Japanese Decision to Grant a Composition of Matter Patent for GR-MD-02
NORCROSS, Ga., April 25, 2017 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis, skin diseases, and cancer, today announced that the Company has received a Decision to Grant from th
Read more →GALTGalectin Therapeutics and Exalenz to Present Late-Breaking Abstract at The International Liver Congress™ 2017
NORCROSS, Ga., April 18, 2017 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, and Exalenz Bioscience (TASE:EXEN), a leader in developing and marketing non-invasive medical devices for diagnosing an
Read more →GALTGalectin Therapeutics Reports 2016 Financial Results and Provides Business Update NORCROSS, Ga. (
Galectin Therapeutics Reports 2016 Financial Results and Provides Business Update NORCROSS, Ga. (March 28, 2017) Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results for the year ended D
Read more →GALTGalectin Therapeutics Issues Statement Regarding GALTW and GALTU
NORCROSS, Ga., March 23, 2017 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, announced today that trading will be halted in GALTW and GALTU at close of business on March 23, 2017 due to the expira
Read more →GALTGalectin Therapeutics Reports Fourth Quarter and Full Year 2016 Financial Results and Provides Business Update
NORCROSS, Ga., March 21, 2017 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, announced today that the Company will release fourth quarter and full year 2016 results before the market opens on Tues
Read more →GALTGR-MD-02 Demonstrates Clinically Significant Effect in Patients with Severe and Refractory Atopic Dermatitis (Eczema) NORCROSS, Ga. (March 14 , 2017) Galectin Therapeutics Inc. (NASDAQ: GALT ), the leading developer of t
GR-MD-02 Demonstrates Clinically Significant Effect in Patients with Severe and Refractory Atopic Dermatitis (Eczema) NORCROSS, Ga. (March 14, 2017) Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today announced
Read more →GALTGalectin Therapeutics to Present at 29th Annual ROTH Conference
NORCROSS, Ga., March 09, 2017 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced that Harold Shlevin, Ph.D., the Company's chief operating officer, will present at the 29th Annual ROTH
Read more →GALTGalectin’s GR-MD-02 Demonstrates Efficacy in Patients with Moderate to Severe Plaque Psoriasis
Research done in partnership with San Antonio Military Medical Center showed an average 50% PASI reduction by end of 24-week treatment period NORCROSS, Ga., March 06, 2017 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that ta
Read more →GALTCombination Immunotherapy with Galectin-3 Inhibitor GR-MD-02 Enhances Effects in Pre-clinical Models and Early Results of Phase 1 Clinical Trials First-in-human data presented at GTCBio 9th Immunotherapeutics & Immunomon
Combination Immunotherapy with Galectin-3 Inhibitor GR-MD-02 Enhances Effects in Pre-clinical Models and Early Results of Phase 1 Clinical Trials First-in-human data presented at GTCBio 9th Immunotherapeutics & Immunomonitoring Conference NORCROSS, Ga. (February 7, 2017) Galec
Read more →GALTGalectin Therapeutics | NASDAQ:GALT This presentation contains, in addition to historical information, forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statemen
Corporate Presentation February 2, 2017 NASDAQ: GALT www.galectintherapeutics.com 2017 Galectin Therapeutics Inc. Exhibit 99.1 2016 Galectin Therapeutics | NASDAQ:GALT This presentation contains, in addition to historical information, forward-looking statements within the mean
Read more →GALTGalectin Therapeutics Announces Achievement of Key Milestones Related to NASH-CX Clinical Trial NORCROSS, Ga. (
Galectin Therapeutics Announces Achievement of Key Milestones Related to NASH-CX Clinical Trial NORCROSS, Ga. (February 1, 2017) Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today announced it has generated suff
Read more →GALTGALECTIN THERAPEUTICS ANNOUNCES $4 MILLION IN NEW EQUITY FINANCINGS Common and Preferred private placements completed at above market prices NORCROSS, Ga. (
GALECTIN THERAPEUTICS ANNOUNCES $4 MILLION IN NEW EQUITY FINANCINGS Common and Preferred private placements completed at above market prices NORCROSS, Ga. (December 29, 2016) Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin
Read more →GALTGalectin Therapeutics to Webcast Corporate Update At Annual Meeting of Stockholders
NORCROSS, Ga., Dec. 08, 2016 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced that the Company will present a corporate update via live webcast immediately following the business por
Read more →GALTGALECTIN THERAPEUTICS ANNOUNCES POSITIVE NEW PSORIASIS AND ATOPIC DERMATITIS CLINICAL DATA, SEEKING STRATEGIC PARTNERSHIPS FOR THERAPY OF SEVERE SKIN DISEASES Meaningful activity of GR-MD-02 in treating psoriasis and pre
GALECTIN THERAPEUTICS ANNOUNCES POSITIVE NEW PSORIASIS AND ATOPIC DERMATITIS CLINICAL DATA, SEEKING STRATEGIC PARTNERSHIPS FOR THERAPY OF SEVERE SKIN DISEASES Meaningful activity of GR-MD-02 in treating psoriasis and preliminary atopic dermatitis suggests promise in treatment
Read more →GALTGalectin Therapeutics Reports Third Quarter 2016 Financial Results and Provides Business Update NORCROSS, Ga. (
Galectin Therapeutics Reports Third Quarter 2016 Financial Results and Provides Business Update NORCROSS, Ga. (November 8, 2016) Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, today r
Read more →GALTGalectin Therapeutics to Webcast Corporate Presentation at the MicroCap Conference on October 25 in Philadelphia
NORCROSS, Ga., Oct. 17, 2016 (GLOBE NEWSWIRE) -- Galectin Therapeutics (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, today announced that Peter G. Traber, M.D., the company's president, chief executive officer and
Read more →GALTGalectin Therapeutics to Present Clinical Data on Selective Non-Invasive Tests for the Development of Novel Therapies for Nonalcoholic Steatohepatitis
NORCROSS, Ga., Oct. 07, 2016 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, today announced it will present two posters that demonstrate the use of alternative non-inv
Read more →GALTGalectin Therapeutics Announces Top-Line Data from Exploratory Phase 2a Pilot Trial (NASH-FX) with GR-MD-02 in NASH Patients with Advanced Fibrosis Larger phase 2b clinical trial in NASH cirrhosis (NASH-CX) now completel
Galectin Therapeutics Announces Top-Line Data from Exploratory Phase 2a Pilot Trial (NASH-FX) with GR-MD-02 in NASH Patients with Advanced Larger phase 2b clinical trial in NASH cirrhosis (NASH-CX) now completely enrolled Closed private placement financing for $1.5 million Con
Read more →GALTGalectin Therapeutics to Present at Rodman & Renshaw 18th Annual Global Investment Conference
NORCROSS, Ga., Aug. 31, 2016 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, today announced that Peter G. Traber, M.D., the Company's president, chief executive office
Read more →GALTGALECTIN THERAPEUTICS ANNOUNCES RESULTS FROM 12-WEEK EXTENSION OF PHASE 2A PSORIASIS CLINICAL TRIAL Meaningful activity of GR-MD-02 in treating psoriasis suggests promise in treatment of non-alcoholic steatohepatitis (NA
GALECTIN THERAPEUTICS ANNOUNCES RESULTS FROM 12-WEEK EXTENSION OF PHASE 2A PSORIASIS CLINICAL TRIAL Meaningful activity of GR-MD-02 in treating psoriasis suggests promise in treatment of non-alcoholic steatohepatitis (NASH), the company s primary NORCROSS, Ga. (August 25, 2016)
Read more →GALTGalectin Therapeutics Reports Second Quarter 2016 Financial Results and Provides Business Update Top-line data from NASH-FX trial in NASH patients with advanced fibrosis expected to be reported by the end of September Au
Galectin Therapeutics Reports Second Quarter 2016 Financial Results and Provides Business Update Top-line data from NASH-FX trial in NASH patients with advanced fibrosis expected to be reported by the end of September Australian patent allowance strengthens global intellectua
Read more →GALTGalectin Therapeutics Announces Completion of Patient Recruitment in its Phase 2 Trial with GR-MD-02 in NASH Patients with Cirrhosis NORCROSS, GA.
Galectin Therapeutics Announces Completion of Patient Recruitment in its Phase 2 Trial with GR-MD-02 in NASH Patients with Cirrhosis NORCROSS, GA. August 2, 2016) Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins to
Read more →GALTGalectin Therapeutics Announces Positive Preclinical Results on the Role of Galectin-3 in Mediating Vascular Remodeling in Pulmonary Arterial Hypertension
NORCROSS, Ga., June 02, 2016 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, reports that GR-MD-02, its development-stage galectin-3 (gal-3) inhibitor, has shown a pos
Read more →GALTGalectin Therapeutics Announces Positive Interim Results from Phase 2a Trial with GR-MD-02 in Moderate-to-Severe Plaque Psoriasis A significant clearing of psoriasis in first four patients prompts the extension of treatm
Galectin Therapeutics Announces Positive Interim Results from Phase 2a Trial with GR-MD-02 in Moderate-to-Severe Plaque Psoriasis A significant clearing of psoriasis in first four patients prompts the extension of treatment for an additional 12 weeks Conference call to be hel
Read more →GALTGalectin Therapeutics Announces Complete Enrollment in its Phase 2 Trial with GR-MD-02 in NASH Patients with Advanced Fibrosis Top line results of the NASH-FX trial to be reported in September 2016 NORCROSS, GA. (
Galectin Therapeutics Announces Complete Enrollment in its Phase 2 Trial with GR-MD-02 in NASH Patients with Advanced Fibrosis Top line results of the NASH-FX trial to be reported in September 2016 NORCROSS, GA. (May 11, 2016) Galectin Therapeutics Inc. (NASDAQ: GALT), the lea
Read more →GALTGalectin Therapeutics Reports First Quarter 2016 Financial Results and Provides Business Update NORCROSS, Ga. (
Galectin Therapeutics Reports First Quarter 2016 Financial Results and Provides Business Update NORCROSS, Ga. (May 10, 2016) Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, today repor
Read more →GALTGalectin Therapeutics to Present at Needham & Company’s 15th Annual Healthcare Conference
NORCROSS, Ga., April 07, 2016 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, today announced that Peter G. Traber, M.D., the Company’s president, chief executive offic
Read more →GALTGalectin Therapeutics Reports 2015 Financial Results and Provides Business Update - Conference Call to Begin at 8:30 a.m. ET Today- NORCROSS, Ga. (
Galectin Therapeutics Reports 2015 Financial Results and Provides Business Update -Conference Call to Begin at 8:30 a.m. ET Today- NORCROSS, Ga. (March 15, 2016) Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins to t
Read more →GALTGalectin Therapeutics to Hold Business Update Conference Call on March 15
NORCROSS, Ga., March 08, 2016 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, announces that in conjunction with the filing of its annual report on form 10-K, it will
Read more →GALTGalectin Therapeutics to Present at the 28th Annual ROTH Conference
NORCROSS, Ga., March 07, 2016 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, announces today Peter G. Traber, M.D., the Company’s president, chief executive officer a
Read more →GALTGalectin Therapeutics Receives U.S. Patent Allowance for GR-MD-02 to Treat Pulmonary Fibrosis
NORCROSS, Ga. , Feb. 24, 2016 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, announces receipt of a Notice of Allowance from the United States Patent and Trademark Of
Read more →GALTGalectin Therapeutics to Present at Upcoming Conferences
NORCROSS, Ga., Jan. 28, 2016 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, announced today Peter G. Traber, MD, the Company’s president, chief executive officer and
Read more →GALTGalectin Therapeutics Inc., to Present at Noble Financial Capital Markets’ 12th Annual Investor Conference
NORCROSS, Ga., Jan. 14, 2016 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, announced today Peter Traber, M.D., the Company’s president, chief executive officer and c
Read more →GALTGalectin Therapeutics Appoints Dr. Marc Rubin Chairman of the Board of Directors NORCROSS, Ga. (
Galectin Therapeutics Appoints Dr. Marc Rubin Chairman of the Board of Directors NORCROSS, Ga. (January 8, 2016) Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, announces the election
Read more →GALTGalectin Therapeutics Posts 2015-2016, Progress and Possibilities to Corporate Website NORCROSS, Ga. (
Galectin Therapeutics Posts 2015-2016, Progress and Possibilities to (January 7, 2016) Galectin Therapeutics, Inc. (Nasdaq: GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, announces that the year-in-review post 2015-2016,
Read more →GALTGalectin Therapeutics Announces Dismissals of Federal Securities Class Action and Shareholder Derivative Actions United States District Court Dismisses both Actions with Prejudice NORCROSS, Ga. (
Galectin Therapeutics Announces Dismissals of Federal Securities Class Action and Shareholder Derivative Actions United States District Court Dismisses both Actions with Prejudice NORCROSS, Ga. (January 5, 2016) Galectin Therapeutics, Inc. (Nasdaq: GALT), the leading developer
Read more →GALTGalectin Therapeutics Announces Pricing of $9.8 Million Registered Direct Offering NORCROSS, Ga. ( November 20 , 2015) Galectin Therapeutics Inc. (NASDAQ: GALT ), the leading developer of therapeutics that target galecti
Galectin Therapeutics Announces Pricing of $9.8 Million Registered Direct Offering Ga. (November 20, 2015) Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, today announced that it has en
Read more →GALTGalectin Therapeutics Reports Third Quarter 2015 Financial Results and Provides Business Update NORCROSS, Ga. (
Galectin Therapeutics Reports Third Quarter 2015 Financial Results and Provides Business Update NORCROSS, Ga. (November 9, 2015) Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, today re
Read more →GALTGalectin Therapeutics Selected to Present at Cavendish Global Health Impact Forum
NORCROSS, Ga., Oct. 23, 2015 (GLOBE NEWSWIRE) -- Galectin Therapeutics (Nasdaq:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, announced today it has been selected to present at the Cavendish Global Health Impact Forum co-h
Read more →GALTGalectin Therapeutics GR-MD-02 to be Studied in Combination with Keytruda in Patients with Metastatic Melanoma Providence Cancer Center Submits IND for Phase 1b Trial NORCROSS, Ga. (
Galectin Therapeutics GR-MD-02 to be Studied in Combination with Keytruda in Patients with Metastatic Melanoma Providence Cancer Center Submits IND for Phase 1b Trial NORCROSS, Ga. (October 19, 2015) Galectin Therapeutics, Inc. (Nasdaq: GALT), the leading developer of therapeu
Read more →GALTGalectin Therapeutics' Executive Chairman to Discuss Silent Epidemic and Company's Role in Developing Treatments for NASH and Other Diseases at Robins Equity Research Roundup Conference
NORCROSS, Ga., Oct. 7, 2015 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, today announced that James Czirr, the Company's Executive Chairman will present at the Robin
Read more →GALTGalectin Therapeutics, Inc. Executive Chairman Jim Czirr to Be Interviewed on "The Big Biz Show"
NORCROSS, GA--(Marketwired - Oct 6, 2015) - Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, announced today that Executive Chairman Jim Czirr will be interviewed on "The Big Biz Show" ho
Read more →GALTGalectin Therapeutics Begins Phase 2a Psoriasis Study With GR-MD-02
NORCROSS, Ga., Sept. 24, 2015 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, announces the start of a 10-patient pilot study with GR-MD-02 in patients with moderate-to
Read more →GALTGalectin Therapeutics to Present at 2015 Ladenburg Thalmann Healthcare Conference
NORCROSS, Ga., Sept. 22, 2015 (GLOBE NEWSWIRE) -- Galectin Therapeutics (Nasdaq:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, announced today that Peter G. Traber, M.D., chief executive officer, president, and chief medic
Read more →GALTGalectin Therapeutics Announces Start of Phase 2 Clinical Trial with GR-MD-02 in NASH with Advanced Fibrosis Second trial in GR-MD-02 Phase 2 program features non-invasive endpoints and shorter treatment duration; data r
Galectin Therapeutics Announces Start of Phase 2 Clinical Trial with GR-MD-02 in NASH with Advanced Second trial in GR-MD-02 Phase 2 program features non-invasive endpoints and shorter treatment duration; data readout expected in the third quarter of 2016 NORCROSS, Ga. (Septem
Read more →GALTGalectin Therapeutics | NASDAQ:GALT This presentation contains, in addition to historical information, forward looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statemen
J. Derm Sci. 2011;64:85 91 2 Lacina L, et al. Folia Biologica. 2006;52:10 15 Study Indication Endpoints Start Data Reporting Phase 1b: Yervoy Advanced melanoma Safety ir RECIST Immune markers Underway Dose Group 1: complete Dose Group 2: complete Dose Group 3: initiated Phase 1b:
Read more →GALTGalectin Therapeutics to Participate in Three Investment Conferences in September
NORCROSS, Ga., Sept. 8, 2015 (GLOBE NEWSWIRE) -- Galectin Therapeutics (Nasdaq:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, announces that executive management will be participating in three investment conferences in Sep
Read more →GALTClinical Trial to Establish Efficacy of GR-MD-02 in NASH Cirrhosis In late June 2015, Galectin Therapeutics initiated a Phase 2 clinical trial (the NASH-CX trial) to evaluate the ability of its anti-galectin drug GR-MD-0
Clinical Trial to Establish Efficacy of GR-MD-02 in NASH Cirrhosis In late June 2015, Galectin Therapeutics initiated a Phase 2 clinical trial (the NASH-CX trial) to evaluate the ability of its anti-galectin drug GR-MD-02 to treat patients with cirrhosis of the liver due to fat
Read more →GALTGalectin Therapeutics Receives U.S. Patent Notice of Allowance for Use of Pectin Compounds to Reduce Fibrosis in Multiple Diseases
NORCROSS, Ga., Aug. 13, 2015 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, announces receipt of a Notice of Allowance from the U.S. Patent and Trademark Office for pa
Read more →GALTGalectin Therapeutics Provides Phase 2 NASH Program Update and Reports Second Quarter 2015 Financial Results NORCROSS, Ga. (
Galectin Therapeutics Provides Phase 2 NASH Program Update and Reports Second Quarter 2015 (August 10, 2015) Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, today reported financial resu
Read more →GALTGalectin Therapeutics Inc. Appoints Adam E. Allgood, Pharm.D., R.Ph., as Executive Director of Clinical Development
NORCROSS, Ga., July 15, 2015 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, today announced the appointment of Adam E. Allgood, Pharm.D., R.Ph. as executive director o
Read more →GALTGalectin Therapeutics Initiates Enrollment for GR-MD-02 Phase 2 Clinical Trial in NASH with Cirrhosis
NORCROSS, Ga., June 29, 2015 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), a leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, today announced the screening of the first five patients in its Phase 2 clinical trial with G
Read more →GALTGalectin Therapeutics Names Dr. Marc Rubin Lead Independent Director
NORCROSS, Ga., June 3, 2015 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (Nasdaq:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, reports that Marc Rubin, M.D. has been elected by the independent members of the board of di
Read more →GALTGalectin Therapeutics to Present at LD Micro Invitational Conference
NORCROSS, Ga., May 28, 2015 (GLOBE NEWSWIRE) -- Galectin Therapeutics (Nasdaq:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, announced today that James Czirr, executive chairman, will present a corporate overview and updat
Read more →GALTGalectin Therapeutics to Webcast Corporate Update Following Annual Meeting of Stockholders
NORCROSS, Ga., May 15, 2015 (GLOBE NEWSWIRE) -- Galectin Therapeutics (Nasdaq:GALT) will webcast a corporate update at 9:45 A.M. ET on Thursday, May 21, 2015, immediately following the business portion of the Company's Annual Meeting of Stockholders. Additionally, Peter Traber, M
Read more →GALTGalectin Therapeutics Reports no Drug-Drug Interaction between GR-MD-02 and Midazolam Phase 1 pharmacokinetic study conducted in accordance with FDA requirements; results add to the GR-MD-02 safety profile and allow for
Galectin Therapeutics Reports no Drug-Drug Interaction between GR-MD-02 and Midazolam Phase 1 pharmacokinetic study conducted in accordance with FDA requirements; results add to the GR-MD-02 safety profile and allow for expansion of number of patients eligible to be included in
Read more →GALTGalectin Therapeutics Reports First Quarter 2015 Financial Results, Provides Business Update Including Phase 2 NASH Program NORCROSS, Ga. (
Galectin Therapeutics Reports First Quarter 2015 Financial Results, Provides Business Update Including Phase 2 NASH Program NORCROSS, Ga. (May 11, 2015) Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins to treat fibr
Read more →GALTGalectin Therapeutics Presented Research With GR-MD-02 at the American Association for the Study of Liver Diseases Industry Colloquium
NORCROSS, Ga., March 24, 2015 (GLOBE NEWSWIRE) -- Galectin Therapeutics (Nasdaq:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, announces that Peter G. Traber, M.D., president, chief executive officer and chief medical offi
Read more →GALTGalectin Therapeutics Reports 2014 Financial Results, Provides Business Update NORCROSS, Ga. (
Galectin Therapeutics Reports 2014 Financial Results, Provides Business Update NORCROSS, Ga. (March 18, 2015) Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, today reported financial re
Read more →GALTGalectin Therapeutics Engages PPD to Conduct GR-MD-02 Phase 2 Trial in NASH, Submits Special Protocol Assessment to FDA Study Enrollment to Begin in the Second Quarter NORCROSS, Ga. (
Galectin Therapeutics Engages PPD to Conduct GR-MD-02 Phase 2 Trial in NASH, Submits Special Protocol Assessment to FDA Study Enrollment to Begin in the Second Quarter NORCROSS, Ga. (March 12, 2015) Galectin Therapeutics (Nasdaq: GALT), the leading developer of therapeutics th
Read more →GALTGalectin Therapeutics to Present at the 27th Annual ROTH Conference
NORCROSS, Ga., March 2, 2015 (GLOBE NEWSWIRE) -- Galectin Therapeutics (Nasdaq:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, announced today that Harold, Shlevin, Ph.D, chief operating officer, will present a corporate ov
Read more →GALTFINAL DRAFT FEBRUARY 23, 2015 Galectin Therapeutics Announces Details of the Design of its Phase 2 Program with GR-MD-02 Program to include one trial to confirm the safety and therapeutic effect on fibrosis in NASH patie
Galectin Therapeutics Announces Details of the Design of its Phase 2 Program with GR-MD-02 Ga. (February 24, 2015) Galectin Therapeutics (Nasdaq: GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, announces details of the des
Read more →GALTGalectin Therapeutics Announces Details of the Design of Its Phase 2 Program With GR-MD-02
Program to include one trial to confirm the safety and therapeutic effect on fibrosis in NASH patients with cirrhosis, and a smaller trial to confirm the safety and therapeutic effect on NASH patients with advanced fibrosis Both studies to begin in the second quarter of 2015 Co
Read more →GALTGalectin Therapeutics | NASDAQ:GALT Forward Looking Statements This presentation contains, in addition to historical information, forward looking statements within the meaning of the Private Securities Litigation Reform
Mean standard deviation 2. Placebo values were combined for all three cohorts because there were no differences (n=19 separate data points) 3. Not significant versus placebo, two sided t test (n=6) 4. Not significant versus placebo, two sided t test (n=7) 5. Significant for three
Read more →GALTFINAL DRAFT-2 JANUARY 6, 2015 Final Phase 1 Trial Results Demonstrate Galectin Therapeutics GR-MD-02 is Safe with Potential For Therapeutic Effect on Fibrosis in NASH Patients with Advanced Fibrosis NORCROSS, Ga. (
Final Phase 1 Trial Results Demonstrate Galectin Therapeutics GR-MD-02 is Safe with Potential For Therapeutic Effect on Fibrosis in NASH Patients with Advanced Fibrosis NORCROSS, Ga. (January 7, 2015) Galectin Therapeutics (Nasdaq: GALT), the leading developer of therapeutics
Read more →GALTGalectin Therapeutics to Present at 7th Annual LD Micro Main Event Conference
NORCROSS, Ga., Dec. 1, 2014 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (Nasdaq:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, announced today that James C. Czirr, executive chairman of the Company's board of directors,
Read more →GALTGalectin Therapeutics Reports Third Quarter 2014 Financial Results and Provides Update on Company s Development Program Norcross, GA (
Galectin Therapeutics Reports Third Quarter 2014 Financial Results and Provides Update on Company s Norcross, GA (November 10, 2014) Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, toda
Read more →GALTAuthor Disclosures Stephen A. Harrison Advisory Committees or Review Panels; Merck, Nimbus Discovery, NGM Bio, Fibrogen. Grant/Research Support: Merck, Genentech; Speaking and Teaching: Merck, Gilead, Janssen, AbbVie. Na
Includes following serum levels: alpha 2 macroglobulin, haptoglobin, apolipoprotein A1, gamma glutamyl transpeptidase, and total bilirubin 13 Results: FibroTest (FibroSure ) Scores 14 * Placebo values were combined after showing that there was no difference between different time
Read more →GALTGalectin Therapeutics' Phase 1 Data Presented at AASLD Annual Meeting Advances GR-MD-02 Into Phase 2 Clinical Development
NORCROSS, Ga., Nov. 9, 2014 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (Nasdaq:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, presented data today from the Company's Phase 1 clinical trial of GR-MD-02 in NASH (fatty li
Read more →GALTGalectin Therapeutics' Abstract Accepted as Oral Presentation at The Liver Meeting(R), Annual Meeting of the American Association for the Study of Liver Diseases
NORCROSS, Ga., Oct. 1, 2014 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (Nasdaq:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, today announced that the Company's abstract titled "Early phase 1 clinical trial results of
Read more →GALTGALECTIN 72 HOUR DEADLINE ALERT: Approximately 72 Hours Remain; Former Louisiana Attorney General and Kahn Swick & Foti, LLC Remind Investors of Deadline in Securities Class Action Lawsuit Against Galectin Therapeutics Inc. - GALT
NEW ORLEANS, LA--(Marketwired - Sep 26, 2014) - Kahn Swick & Foti, LLC ("KSF") and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors with large financial interests that they have only until September 29, 2014 to file lead plaintiff appl
Read more →GALTGalectin Therapeutics Elects Gilbert S. Omenn, M.D., Ph.D., a Leading Cancer Researcher, to Its Board of Directors
NORCROSS, Ga., Sept. 24, 2014 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (Nasdaq:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, today announced the election of Gilbert S. Omenn, M.D., Ph.D., to its Board of Directors,
Read more →GALTGALECTIN SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Reminds Investors With Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Galectin Therapeutics Inc. - GALT
NEW ORLEANS, Sept. 15, 2014 (GLOBE NEWSWIRE) -- Kahn Swick & Foti, LLC ("KSF") and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until September 29, 2014 to file lead plaintiff applications in a securities class actio
Read more →GALTGalectin Therapeutics Announces Issuance of U.S. Patent for GR-MD-02 in Diabetic Nephropathy Norcross, Ga. (
Galectin Therapeutics Announces Issuance of U.S. Patent for GR-MD-02 in Diabetic Nephropathy Norcross, Ga. (September 15, 2014) Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, today ann
Read more →GALTForward Looking Statement Disclaimer 2 2014 Galectin Therapeutics | NASDAQ:GALT This presentation contains, in addition to historical information, forward looking statements within the meaning of the Private Securities L
Eliezer Zomer, PhD Manufacturing and Product Development Head Executive VP of Manufacturing Product Development Galectin Therapeutics Founder of Alicon Biological Control VP of Product Development Safe Sciences, Inc. VP of R D Charm Sciences, Inc. Elena Chekova, PhD Program Manag
Read more →GALTGalectin Therapeutics to Present at Aegis Capital Corporation 2014 Healthcare and Technology Conference
NORCROSS, Ga., Sept. 10, 2014 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (Nasdaq:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, today announced the Company will present at the Aegis Capital Corporation 2014 Healthcare
Read more →GALTGALECTIN SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Reminds Investors with Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Galectin Therapeutics Inc. - GALT
NEW ORLEANS, Aug. 15, 2014 (GLOBE NEWSWIRE) -- Kahn Swick & Foti, LLC ("KSF") and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until September 29, 2014 to file lead plaintiff applications in a securities class action
Read more →GALTGalectin Therapeutics Reports Second Quarter 2014 Financial Results Norcross, GA (
Galectin Therapeutics Reports Second Quarter 2014 Financial Results Norcross, GA (August 7, 2014) Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, today reported its financial results fo
Read more →GALTGalectin Therapeutics Receives U.S. Patent for GR-MD-02 Composition of Matter Patent Covers Use of Company s Galectin Inhibitor in NASH, Fibrotic Diseases, Cancer and Other Disorders in Which Galectins are Involved in Pa
Galectin Therapeutics Receives U.S. Patent for GR-MD-02 Composition of Matter Patent Covers Use of Company s Galectin Inhibitor in NASH, Fibrotic Diseases, Cancer and Other Disorders in Which Galectins are Involved in Pathogenesis Norcross, Ga. (August 5, 2014) Galectin Thera
Read more →GALTGalectin Therapeutics Responds to Class Action Lawsuit
NORCROSS, Ga., Aug. 4, 2014 (GLOBE NEWSWIRE) -- Galectin Therapeutics (Nasdaq:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, issued the following statement today. We have become aware that a putative class action lawsuit
Read more →GALTGALECTIN SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Reminds Investors with Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Galectin Therapeutics Inc. -- GALT
NEW ORLEANS, July 31, 2014 (GLOBE NEWSWIRE) -- Kahn Swick & Foti, LLC ("KSF") and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until September 29, 2014 to file lead plaintiff applications in a securities class action
Read more →GALTGalectin Therapeutics Issues Statement on GR-MD-02 Development Program
NORCROSS, Ga., July 30, 2014 (GLOBE NEWSWIRE) -- Galectin Therapeutics (Nasdaq:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, announced yesterday results of cohort 2 of its phase 1 clinical trial in patients with NASH with
Read more →GALTForward Looking Statement This presentation contains, in addition to historical information, forward looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements relate
The number of patients in the third cohort will be expanded to 20 total patients (12 active drug and 8 placebo) which will allow comparison of 12 patients in each group in analysis of the data (including 4 placebos from previous cohorts). Blood biomarker analysis will be conducte
Read more →GALTGalectin Therapeutics to Host Webcast to Discuss Findings From Cohort 2 of Phase 1 Clinical Trial of GR-MD-02 in Fatty Liver Disease With Advanced Fibrosis
NORCROSS, Ga., July 25, 2014 (GLOBE NEWSWIRE) -- Galectin Therapeutics (Nasdaq:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, announced the Company will hold a webcast on Tuesday, July 29, 2014 at 8:30 a.m. Eastern Dayligh
Read more →GALTGalectin Therapeutics Announces First Patient Dosed in Cohort 1 of Phase 1B Clinical Trial of GR-MD-02 in Combination with Ipilimumab in Metastatic Melanoma Trial Conducted by Providence Portland Medical Center, a Leadin
Galectin Therapeutics Announces First Patient Dosed in Cohort 1 of Phase 1B Clinical Trial of GR-MD-02 in Combination with Ipilimumab in Metastatic Melanoma Trial Conducted by Providence Portland Medical Center, a Leading Cancer Immunotherapy Research Institute Norcross, Ga.
Read more →GALTGalectin Therapeutics Added to Russell 2000 Index
NORCROSS, Ga., July 9, 2014 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (Nasdaq:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, announced that it has been added to the Russell 3000 Index and Russell 2000 Index when Russe
Read more →GALTGalectin Therapeutics Announces That Oral Treatment With Galectin-3 Inhibitor GR-MD-02 is Efficacious in Preclinical Model of Fatty Liver Disease With Fibrosis
NORCROSS, Ga., June 23, 2014 (GLOBE NEWSWIRE) -- Galectin Therapeutics (Nasdaq:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, announced today that a preclinical study in a mouse model of NASH (non-alcoholic steatohepatitis
Read more →GALTGalectin Therapeutics to Present at Jefferies 2014 Global Healthcare Conference
NORCROSS, Ga., May 29, 2014 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (Nasdaq:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, today announced that the Company will present at the Jefferies 2014 Global Healthcare Confer
Read more →GALTGalectin Therapeutics Receives U.S. Patent for GR-MD-02 in Diabetic Nephropathy, a Progressive Kidney Disease Norcross, Ga. (
Galectin Therapeutics Receives U.S. Patent for GR-MD-02 in Diabetic Nephropathy, a Progressive Kidney Disease Norcross, Ga. (May 28, 2014) Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cance
Read more →GALTForward Looking Statement Disclaimer This presentation contains, in addition to historical information, forward looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These stateme
Chiles Initial funding of clinical trial by PPMC/EACRI. Galectin is providing GR MD 02 study drug, reference to its IND, and PK analysis Ongoing discussions with large pharmaceutical companies in the immunotherapy space to seek a partnering opportunity at the most opportune time
Read more →GALTGalectin Therapeutics Reports First Quarter 2014 Financial Results Norcross, GA (
Galectin Therapeutics Reports First Quarter 2014 Financial Results Norcross, GA (May 13, 2014) Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, today reported its financial results for t
Read more →GALTGalectin Therapeutics to Hold Conference Call to Provide Corporate Update Following Company s Annual Meeting of Shareholders Atlanta, GA.
Galectin Therapeutics to Hold Conference Call to Provide Corporate Update Following Company s Annual Meeting of Shareholders Atlanta, GA., May 8, 2014 Galectin Therapeutics (NASDAQ: GALT) will host a conference call at 9:45 A.M. Eastern Time on Wednesday, May 14, 2014, to prov
Read more →GALTGalectin Therapeutics Completes Enrollment of Second Cohort of Phase 1 Trial of
FOR RELEASE 4/23/2014 Galectin Therapeutics Completes Enrollment of Second Cohort of Phase 1 Trial of GR-MD-02 for NASH (Fatty Liver Disease) with Advanced Fibrosis Norcross, GA, April 23, 2014 Galectin Therapeutics (NASDAQ:GALT), the leading developer of therapeutics that tar
Read more →GALTGalectin Therapeutics Completes Enrollment of Second Cohort of Phase 1 Trial of GR-MD-02 for NASH (Fatty Liver Disease) With Advanced Fibrosis
NORCROSS, Ga., April 23, 2014 (GLOBE NEWSWIRE) -- Galectin Therapeutics (Nasdaq:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, announced today that all eight (8) patients have received their first infusion in cohort 2 of i
Read more →GALTGalectin Therapeutics Announces First Patient Dosed in Second Cohort of Phase 1 Trial of GR-MD-02 for NASH With Advanced Fibrosis
NORCROSS, Ga., April 17, 2014 (GLOBE NEWSWIRE) -- Galectin Therapeutics (Nasdaq:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, announced today that the first patient in cohort 2 of its Phase 1 clinical trial of GR-MD-02 in
Read more →GALTGalectin Therapeutics to Announce Results from First Cohort of Phase 1 Clinical Trial in Fatty Liver Disease Company to Hold Webcast and Conference Call on April 1 to Review Findings Norcross, Ga.
Galectin Therapeutics to Announce Results from First Cohort of Phase 1 Clinical Trial in Fatty Liver Disease Company to Hold Webcast and Conference Call on April 1 to Review Findings Norcross, Ga., March 25, 2014 Galectin Therapeutics (Nasdaq:GALT), the leading developer of th
Read more →GALTGalectin Therapeutics Reports 2013 Financial Results Norcross, GA (
Galectin Therapeutics Reports 2013 Financial Results Norcross, GA (March 21, 2014) Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, today reported its financial results for the year ende
Read more →GALTGalectin Therapeutics Secures U.S. Patent for its Proprietary Galectin Inhibitor GR-MD-02 in Fatty Liver Disease Norcross, Ga.
Galectin Therapeutics Secures U.S. Patent for its Proprietary Galectin Inhibitor GR-MD-02 in Fatty Liver Disease Norcross, Ga., February 26, 2014 Galectin Therapeutics (Nasdaq:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and canc
Read more →GALTGalectin Therapeutics Presents at JMP Securities' Nonalcoholic Steatohepatitis (NASH) Workshop
NORCROSS, Ga., Feb. 24, 2014 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (Nasdaq:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, today announced that the Company will present at the Nonalcoholic Steatohepatitis (NASH) Wo
Read more →GALTGalectin Therapeutics CEO Serves on Cancer Immunotherapy Panel at BIO CEO & Investor Conference Noteworthy Panel of Oncology Experts Focuses on Immunotherapy as an Important Cancer Treatment Modality Norcross, Ga. (
Galectin Therapeutics CEO Serves on Cancer Immunotherapy Panel at BIO CEO & Investor Conference Noteworthy Panel of Oncology Experts Focuses on Immunotherapy as an Important Cancer Treatment Modality Norcross, Ga. (February 13, 2014) Galectin Therapeutics Inc. (NASDAQ: GALT),
Read more →GALTForward Looking Statements This presentation contains, in addition to historical information, statements that look forward in time or that express management s beliefs, expectations or hopes. Such statements are forward
Galectin is providing GR MD 02 study drug, reference to its IND, and PK analysis Ongoing discussions with large pharmaceutical companies in the immunotherapy space to seek a partnering opportunity to take beyond proof of concept from initial clinical trials 31 2014 Galectin Thera
Read more →GALTGalectin Therapeutics to Present at 16 th Annual BIO CEO & Investor Conference Norcross, Ga. (
Galectin Therapeutics to Present at 16th Annual BIO CEO & Investor Conference Norcross, Ga. (February 5, 2014) Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, today announced that the
Read more →GALTGalectin Therapeutics to Present at 16th Annual BIO CEO & Investor Conference
NORCROSS, Ga., Feb. 5, 2014 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (Nasdaq:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, today announced that the Company will present at the 16th Annual BIO CEO & Investor Conferen
Read more →GALTGalectin Therapeutics and Providence Portland Medical Center Receive OK from FDA to Proceed with Phase 1B Clinical Trial in Metastatic Melanoma Norcross, Ga. (
Galectin Therapeutics and Providence Portland Medical Center Receive OK from FDA to Proceed with Phase 1B Clinical Trial in Metastatic Melanoma Norcross, Ga. (Feb. 3, 2014) Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin pr
Read more →GALTGalectin Therapeutics Inc. and SBH Sciences, Inc. Announce the Formation of Galectin Sciences, LLC, a Collaborative Venture to Research and Develop Galectin Inhibitors for Oral Administration NORCROSS, Ga., and NATICK, M
Galectin Therapeutics Inc. and SBH Sciences, Inc. Announce the Formation of Galectin Sciences, LLC, a Collaborative Venture to Research and Develop Galectin Inhibitors for Oral Administration NORCROSS, Ga., and NATICK, Mass. (January 27, 2014) Galectin Therapeutics Inc. (NASDA
Read more →GALTGalectin Therapeutics Executive Chairman James Czirr to Present at RedChip Emerging Growth Showcase
NORCROSS, Ga., Jan. 23, 2014 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (Nasdaq:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, today announced that its executive chairman James Czirr will present during the RedChip Eme
Read more →GALTPreclinical Study Demonstrates Effect of Galectin Inhibitor on Serum Biomarker in Fatty Liver Disease with Fibrosis Norcross, GA (
Preclinical Study Demonstrates Effect of Galectin Inhibitor on Serum Biomarker in Fatty Liver Disease Norcross, GA (January 21, 2014) Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, tod
Read more →GALTGalectin Therapeutics Supports Investigational New Drug (IND) Application for its Galectin Inhibitor GR-MD-02 in Metastatic Melanoma IND Submitted by Providence Portland Medical Center, a Leading Cancer Immunotherapy Res
Galectin Therapeutics Supports Investigational New Drug (IND) Application for its Galectin Inhibitor GR-MD-02 in Metastatic Melanoma IND Submitted by Providence Portland Medical Center, a Leading Cancer Immunotherapy Research Institute Norcross, GA (January 15, 2014) Galectin
Read more →GALTGalectin Therapeutics Announces Completion of Enrollment in First Cohort of Phase 1 Trial of GR-MD-02 in Fatty Liver Disease with Advanced Fibrosis Norcross, GA (
Galectin Therapeutics Announces Completion of Enrollment in First Cohort of Phase 1 Trial of GR-MD-02 in Fatty Liver Disease with Advanced Fibrosis Norcross, GA (January 13, 2014) Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target gale
Read more →GALTGalectin Therapeutics Announces Update on Financing Activities and Cash of $32.3 Million Norcross, GA (
Galectin Therapeutics Announces Update on Financing Activities and Cash of $32.3 Million Norcross, GA (January 10, 2014) Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, today announced
Read more →GALTCorporate Presentation January 2014 NASDAQ: GALT 2014 Galectin Therapeutics www.galectintherapeutics.com NASDAQ:GALT Forward Looking Statements This presentation contains, in addition to historical information, statement
Corporate Presentation Therapeutics www.galectintherapeutics.com Forward Looking Statements contains, in addition to historical information, statements that look forward in time or that express management s beliefs, expectations or hopes. Such statements are forward-looking st
Read more →GALTGalectin Therapeutics Reports on Key 2013 Scientific, Development and Regulatory Milestones, Highlights Corporate and Financial Activity Norcross, GA (
Galectin Therapeutics Reports on Key 2013 Scientific, Development and Regulatory Milestones, Highlights Corporate and Financial Activity Norcross, GA (January 8, 2014) Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins
Read more →GALTGalectin Therapeutics Receives US Patent for Combination Treatment for Liver Fibrosis NORCROSS, Ga.
Galectin Therapeutics Receives US Patent for Combination Treatment for Liver Fibrosis NORCROSS, Ga., Jan. 6, 2014 (GLOBE NEWSWIRE) Galectin Therapeutics (GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, today announced tha
Read more →GALTGalectin Therapeutics Reports Update on Enrollment of First Cohort of Phase 1 Clinical Trial and Third Quarter 2013 Financial Results Norcross, GA (
Galectin Therapeutics Reports Update on Enrollment of First Cohort of Phase 1 Clinical Trial and Third Quarter 2013 (November 12, 2013) Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, t
Read more →GALTGalectin Therapeutics Announces Early Warrant Exercise by 10X Fund, Provides Update on Cash Position Norcross, GA
Galectin Therapeutics Announces Early Warrant Exercise by 10X Fund, Provides Update on Cash Position Norcross, GA, October 17, 2013 Galectin Therapeutics (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, today ann
Read more →GALTGalectin Therapeutics Preclinical Data Published in PLOS ONE Show Its Galectin Inhibitors Reverse Cirrhosis and Significantly Reduce Fibrosis and Portal Hypertension Findings Suggest Role for GR-MD-02 and GM-CT-01 in Tre
Galectin Therapeutics Preclinical Data Published in PLOS ONE Show Its Galectin Inhibitors Reverse Cirrhosis and Significantly Reduce Fibrosis and Portal Hypertension Findings Suggest Role for GR-MD-02 and GM-CT-01 in Treatment of Liver Fibrosis and Cirrhosis in Humans Norcro
Read more →GALTGalectin Therapeutics Leadership to Present at Three Upcoming Conferences Norcross, GA
Galectin Therapeutics Leadership to Present at Three Upcoming Conferences Norcross, GA, September 23, 2013 Galectin Therapeutics (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, today announced that Company leader
Read more →GALTGALECTIN THERAPEUTICS RECEIVES US PATENT FOR POTENTIAL GROUND-BREAKING TREATMENT FOR FATTY LIVER DISEASE Norcross, GA
GALECTIN THERAPEUTICS RECEIVES US PATENT FOR POTENTIAL GROUND-BREAKING TREATMENT FOR FATTY LIVER DISEASE Norcross, GA, September 10, 2013 Galectin Therapeutics (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, toda
Read more →GALTGalectin Therapeutics Announces Update on Warrant Exercises Norcross, GA (
Galectin Therapeutics Announces Update on Warrant Exercises Norcross, GA (August 28, 2013) Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, today announced all of the 710,834 common stoc
Read more →GALTGalectin Therapeutics Announces $3 Million Private Placement of Restricted Stock Norcross, GA (
Galectin Therapeutics Announces $3 Million Private Placement of Restricted Stock Norcross, GA (August 21, 2013) Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, today announced completi
Read more →GALTGalectin Therapeutics Chairman Discusses Details of Fast Track Designation Today at 11 A.M.
ORLANDO, Fla., Aug. 16, 2013 (GLOBE NEWSWIRE) -- RedChip Companies, Inc. ("RedChip"), an international small-cap research, investor relations, and financial media company, today announced that Jim Czirr, executive chairman of Galectin Therapeutics (Nasdaq:GALT), a leading develop
Read more →GALTGalectin Therapeutics Reports Second Quarter 2013 Financial Results Norcross, GA (
Galectin Therapeutics Reports Second Quarter 2013 Financial Results Norcross, GA (August 14, 2013) Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, today reported its financial results f
Read more →GALTFINAL for Release Monday
FINAL for Release Monday, August 12, 2013 Galectin Therapeutics Receives FDA Fast Track Designation for GR-MD-02 for Fatty Liver Disease with Advanced Fibrosis Norcross, GA, August 12, 2013 Galectin Therapeutics (NASDAQ: GALT), the leading developer of therapeutics that target
Read more →GALTGalectin Therapeutics Receives FDA Fast Track Designation for GR-MD-02 for Fatty Liver Disease With Advanced Fibrosis
NORCROSS, Ga., Aug. 12, 2013 (GLOBE NEWSWIRE) -- Galectin Therapeutics (Nasdaq:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, today announced that the U.S. Food and Drug Administration (FDA) has granted GR-MD-O2 (galactoar
Read more →GALTReduction in Lung Fibrosis with the Anti-Galectin Drug GR-MD-02 Revealed in Preclinical Data Results Suggest Role for GR-MD-02 in Treating Idiopathic Pulmonary Fibrosis Norcross, GA
Reduction in Lung Fibrosis with the Anti-Galectin Drug GR-MD-02 Revealed in Preclinical Data Results Suggest Role for GR-MD-02 in Treating Idiopathic Pulmonary Fibrosis Norcross, GA, August 5, 2013 Galectin Therapeutics (NASDAQ: GALT), the leading developer of therapeutics that
Read more →GALTGalectin Therapeutics Announces First Patient Dosed in Phase 1 Trial of GR-MD-02, a Potential First-in-Class Treatment for Fatty Liver Disease with Advanced Fibrosis Norcross, GA
Galectin Therapeutics Announces First Patient Dosed in Phase 1 Trial of GR-MD-02, a Potential First-in-Class Treatment for Fatty Liver Disease with Advanced Fibrosis Norcross, GA, July 24, 2013 Galectin Therapeutics (NASDAQ:GALT), the leading developer of therapeutics that targ
Read more →GALTGalectin Therapeutics Submits Fast Track Application to FDA for GR-MD-02 in Treatment of Fatty Liver Disease with Advanced Fibrosis Norcross, GA
Galectin Therapeutics Submits Fast Track Application to FDA for GR-MD-02 in Treatment of Fatty Liver Disease with Advanced Fibrosis Norcross, GA, July 1, 2013 Galectin Therapeutics (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins to treat fibro
Read more →GALTTumor Immunotherapy Efficacy Increased in Both Breast and Prostate Cancer Preclinical Models with Addition of Galectin Inhibitor Galectin Therapeutics and Earle A. Chiles Research Institute Norcross, GA
Tumor Immunotherapy Efficacy Increased in Both Breast and Prostate Cancer Preclinical Models with Addition of Galectin Inhibitor Galectin Therapeutics and Earle A. Chiles Research Institute Norcross, GA, June 12, 2013 Galectin Therapeutics (NASDAQ: GALT), the leading developer
Read more →GALTGalectin Therapeutics to Hold Conference Call to Provide Update Following Company s Annual Meeting of Shareholders New Phone Number for Audio Portion of Presentation ATLANTA
Galectin Therapeutics to Hold Conference Call to Provide Update Following Company s Annual Meeting of Shareholders New Phone Number for Audio Portion of Presentation ATLANTA, May 23, 2013 /PRNewswire/ Galectin Therapeutics (NASDAQ: GALT) will host a conference call at 9:30 A.M.
Read more →GALTGalectin Therapeutics to Hold Conference Call to Provide Update Following Company s Annual Meeting of Shareholders Atlanta, GA.
Galectin Therapeutics to Hold Conference Call to Provide Update Following Company s Annual Meeting of Shareholders Atlanta, GA., May 15, 2013 Galectin Therapeutics (NASDAQ: GALT) will host a conference call at 9:30 A.M. Eastern Time on Thursday, May 23, 2013, to provide an upd
Read more →GALTGalectin Therapeutics Reports First Quarter 2013 Financial Results Norcross, GA (
Galectin Therapeutics Reports First Quarter 2013 Financial Results Norcross, GA (May 10, 2013) Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, today reported its financial results for t
Read more →GALTGalectin Inhibitors Reverse Liver Cirrhosis in Preclinical Studies Galectin Therapeutics and Icahn School of Medicine at Mount Sinai Data Presented at the International Liver Congress 2013 Norcross, GA
Galectin Inhibitors Reverse Liver Cirrhosis in Preclinical Studies Galectin Therapeutics and Icahn School of Medicine at Mount Sinai Data Presented at the International Liver Congress 2013 Norcross, GA, April 29, 2013 Galectin Therapeutics (NASDAQ: GALT), the leading developer
Read more →GALTGalectin Therapeutics Reports Full Year and Fourth Quarter 2012 Financial Results Norcross, GA (
Galectin Therapeutics Reports Full Year and Fourth Quarter 2012 Financial Results Norcross, GA (March 29, 2013) Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, today reported its financ
Read more →GALTGalectin Therapeutics Corporate Summary
Galectin Therapeutics www.galectintherapeutics.com Forward Looking Statements Galectin Therapeutics This presentation contains, in addition to historical information, statements that look forward in time or that express management s beliefs, expectations or hopes. Such state
Read more →GALTGALECTIN THERAPEUTICS INC. FOR IMMEDIATE RELEASE Galectin Therapeutics Inc. Receives OK from FDA to Proceed with First Human Clinical Trial for Treatment of Fatty Liver Disease with Advanced Fibrosis Norcross, GA
GALECTIN THERAPEUTICS INC. Galectin Therapeutics Inc. Receives OK from FDA to Proceed with First Human Clinical Trial for Treatment of Fatty Liver Disease with Advanced Fibrosis Norcross, GA, March 5, 2013 - Galectin Therapeutics (NASDAQ:GALT), the leading developer of therapeu
Read more →GALTForward Looking Statements This presentation contains, in addition to historical information, forward looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements relate
NASH with Advanced Fibrosis (Fatty Liver Disease) 1/30/13: IND Submitted to FDA 3 4/13: Initiate Phase 1 NASH trial 1/14: Phase 1 NASH trial results Q1 2014: Initiate Phase 2 NASH trial Top line data from Phase 2 trial TBD based on design 31 2013 Galectin Therapeutics NASDAQ:GALT
Read more →GALTGalectin Therapeutics Inc. Announces Submission of an Investigational New Drug (IND) Application for the Treatment of Fatty Liver Disease Norcross, GA
Galectin Therapeutics Inc. Announces Submission of an Investigational New Drug (IND) Application for the Treatment of Fatty Liver Disease Norcross, GA, January 31, 2013 Galectin Therapeutics (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins to tr
Read more →GALTGalectin Therapeutics Presents New Data on the Treatment of Fatty Liver Disease and Fibrosis at AASLD 2012 Norcross, GA
Galectin Therapeutics Presents New Data on the Treatment of Fatty Liver Disease and Fibrosis at AASLD 2012 Norcross, GA, November 12, 2012 Galectin Therapeutics (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, toda
Read more →GALTGalectin Therapeutics Reports Third Quarter 2012 Financial Results Norcross, GA.
Galectin Therapeutics Reports Third Quarter 2012 Financial Results November 9, 2012 Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, today reported its financial results for the third qua
Read more →GALTGalectin Therapeutics Inc. [GALT] to Ring The NASDAQ Stock Market Closing Bell
ADVISORY, Sept. 5, 2012 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc., a pharmaceutical company, will visit the NASDAQ MarketSite in Times Square to celebrate its Initial Public Offering in March of 2012. In honor of the occasion, Dr. Peter Traber, President and CEO, will ring
Read more →GALTGalectin Therapeutics Appoints Harold H. Shlevin, PhD, Bioscience Industry Executive, as Chief Operating Officer Newton, MA
Galectin Therapeutics Appoints Harold H. Shlevin, PhD, Bioscience Industry Executive, as Chief Operating Officer Newton, MA, Aug. 29, 2012 Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer,
Read more →GALTGalectin Therapeutics Reports Second Quarter 2012 Financial Results Newton, Mass.
Galectin Therapeutics Reports Second Quarter 2012 Financial Results Newton, Mass. August 10, 2012 Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, today reported its financial results fo
Read more →GALTGalectin Therapeutics Reports First Quarter 2012 Financial Results Newton, Mass. (
Galectin Therapeutics Reports First Quarter 2012 Financial Results Newton, Mass. (May 11, 2012 Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, today reported its financial results for f
Read more →GALTGalectin Therapeutics Announces Long-term Engagement of Dr. Scott Friedman to Advise on Liver Fibrosis Programs -Renowned Physician and Researcher in Liver Diseases- Newton, MA
Galectin Therapeutics Announces Long-term Engagement of Dr. Scott Friedman to Advise on Liver Fibrosis Programs -Renowned Physician and Researcher in Liver Diseases- 2012 Galectin Therapeutics Inc. (NASDAQ: GALT) ( the Company ), the leader in developing carbohydrate-based ther
Read more →GALTGalectin Therapeutics Reports Full Year and Fourth Quarter 2011 Financial Results Newton, M A . , March 30 , 201 2 Galectin Therapeutics Inc. ( NASDAQ : GALT) , the leading developer of therapeutics that target galectin
Galectin Therapeutics Reports Full Year and Fourth Quarter 2011 Financial Results Newton, MA., March 30, 2012 Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, today reported its financia
Read more →GALTGALECTIN THERAPEUTICS INC. ANNOUNCES PRICING OF PUBLIC OFFERING OF 1,159,445 UNITS, LISTING ON NASDAQ AND EFFECTIVENESS OF REVERSE STOCK SPLIT Newton, MA
GALECTIN THERAPEUTICS INC. ANNOUNCES PRICING OF PUBLIC OFFERING OF 1,159,445 UNITS, LISTING ON NASDAQ AND EFFECTIVENESS OF REVERSE STOCK SPLIT March 22, 2012 Galectin Therapeutics Inc. (NASDAQ: GALT) today announced the pricing of an underwritten public offering of 1,159,445 u
Read more →GALTGALECTIN THERAPEUTICS INC. APPOINTS THOMAS A. MCGAULEY AS ACTING CHIEF FINANCIAL OFFICER AND EXTENDS TERM OF EMPLOYMENT OF MAUREEN E. FOLEY AS CHIEF OPERATING OFFICER Newton, MA
GALECTIN THERAPEUTICS INC. APPOINTS THOMAS A. MCGAULEY AS ACTING CHIEF FINANCIAL OFFICER AND EXTENDS TERM OF EMPLOYMENT OF MAUREEN E. FOLEY AS CHIEF OPERATING Newton, MA March 5, 2012 Galectin Therapeutics Inc. (OTC: GALT) (the Company ) announced today that it has appointed T
Read more →GALTGalectin Therapeutics Provides Corporate Update Newton, MA
Galectin Therapeutics Provides Corporate Update Newton, MA December 19, 2011 Galectin Therapeutics Inc. (OTC: GALT), the leader in developing carbohydrate-based therapeutic compounds to inhibit galectin proteins, today issued the following corporate update to its shareholders:
Read more →GALTGalectin Therapeutics Elects Dr. Marc Rubin to its Board of Directors Newton, MA
Galectin Therapeutics Elects Dr. Marc Rubin to its Board of Directors Newton, MA October 12, 2011- Galectin Therapeutics (OTC: GALT), the leading developer of galectin inhibitor therapeutic compounds to treat fibrosis and cancer, today announced the election of Dr. Marc Rubin
Read more →Competitive Position
How GALT ranks across every disease it competes inCompetitive Position is a premium feature
See how GALT ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial